Insulin Resistance and its Correlation with Severity

of Coronary Artery Disease in Patients without Diabetes by Geetesh, Manik
  
 
“Insulin Resistance and its Correlation with Severity 
of Coronary Artery Disease in Patients without 
Diabetes” 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                     A dissertation submitted to 
The Tamil Nadu Dr. M.G.R. Medical University, 
Chennai 
In partial fulfillment of 
DM - Branch II CARDIOLOGY 
Examination to be held in August 2015 
 
 
 C E R T I F I C A T E 
 
 
This is to certify that the dissertation entitled 
“Insulin Resistance and its Correlation with Severity 
of Coronary Artery Disease in Patients without 
Diabetes” 
is a bonafide work done by 
GEETESH MANIK 
Christian Medical College, Vellore, Tamil Nadu 
in partial fulfillment of the University rules and regulations 
for award of 
DM - Branch II CARDIOLOGY 
under my guidance and supervision 
during the academic year 2012-15 
 
 
 
 
 
 
 
 
 
 
Dr. OOMMEN K. GEORGE, M.D., D.M. 
(Guide) 
Professor  
Dept. of Cardiology, CMC, Vellore 
Dated: 
 
 
 
 
 
Dr. PAUL V. GEORGE, M.D., D.M.   Principal/Dean 
Professor and Head     Christian Medical College, 
Dept. of Cardiology, CMC, Vellore   Vellore 
Dated:       Dated: 
 
 
 
 
 
 
Turnitin Digital Receipt 
 
   
Turnitin Originality Report 
 
 
 
  
 
 
 
 
 
 
 
         Words cannot express the deep sense of gratitude for my teacher and 
guide Prof. Oommen K. George, M.D., D.M., Department of Cardiology, 
Christian Medical College, Vellore under whose guidance and constant 
supervision, this work was completed. His whole hearted co-operation and 
counsel cheered me through and humbled me. 
 
         I also express my sincere thanks to entire senior faculty in the 
department of Cardiology, CMC- Prof. Jacob Jose, Prof. George Joseph, 
Prof. Sunil Chandy, Prof. Paul V. George, Prof. Bobby John, Prof. J. 
Roshan and Prof. Viji S. T. for their invaluable guidance and constant 
encouragement throughout my study period. 
 
         I would especially like to thank from bottom of my heart Associate 
Prof John J for his constant support and invaluable guidance throughout 
the course of my study period. 
 
         I am also thankful to all my colleagues and dear juniors for their 
valuable help and cooperation. 
 
         I also offer my sincere regards and respect to my dear parents and 
cannot forget my beloved wife for her constant support and 
encouragement. 
 
 Last but not the least, I thank to all the patients who agreed to be a 
part of this study and rendered their co-operation. 
 
 
 
 
 
ACKNOWLEDGEMENT 
INDEX 
 
 
Sr. no. Topic Page no. 
1. Abstract 01 
2. Introduction 04 
3. Aims and Objectives 08 
4. Review of Literature 09 
5. Materials and Methods 39 
6. Results 46 
7. Discussion 78 
8. Conclusion 93 
9. Recommendations 95 
10. Bibliography 96 
11. Appendices 
 Appendix I: 
Abbreviations 
 Appendix II: 
Clinical Research Form 
 Appendix III: 
Master Data Sheet 
 
 
 1 
 
ABSTRACT 
Title of the study: 
Insulin resistance and its correlation with severity of Coronary Artery Disease in 
patients without diabetes  
Objectives: 
 Primary Objective 
To estimate insulin resistance and its correlation with severity of Coronary 
Artery Disease (CAD) in non diabetic adult patients aged 30 years and above 
undergoing Coronary angiography in a tertiary care hospital in India. 
 Secondary Objectives 
a) To evaluate the clinical profile/risk factors in non diabetic CAD and to 
study their association with CAD. 
b) To assess regional body composition of fat via DEXA SCAN (Dual 
energy X-ray absorptiometry) and its correlation with severity of CAD 
in Indian Subjects. 
 
Methods: 
This single centre prospective observational study was conducted on consecutive 
non diabetic patients aged 30 years and above, admitted for coronary angiography 
in the general and private wards of Department of Cardiology from August 2013 – 
Dec 2014. A detailed history and physical  / blood examination pertaining to 
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cardiovascular system was performed. After taking informed consent, estimation of 
fasting/postprandial blood sugars, HbA1C / Insulin assay was done and insulin 
resistance was assessed in all subjects prior to coronary angiogram. DEXA Scan 
was done to assess regional and total body composition of fat in all patients. 
Angiographic profile of all patients was evaluated post procedure and the 
population was then stratified into cases (abnormal CAG) and controls (normal 
CAG). The severity of coronary artery disease was also calculated with help of 
Gensini score; the correlation of which was then studied with presence of insulin 
resistance. The correlation between clinical profile of non diabetic CAD and 
presence or absence of insulin resistance was then studied in between both groups. 
The body composition via DEXA was also studied in between two groups. 
 
Results: 
This study showed that association between insulin resistance and coronary artery 
disease was statistically significant (p<0.005). The association was even found to 
be significant when the CAD population was further stratified into low HOMA-IR 
(<3) and high HOMA-IR (≥3) group. In the study 66 CAD cases were further 
stratified into 3 groups (A=1-14; B=15-32; C=≥33). Out of these groups sensitivity 
and specificity of HOMA-IR and QUICKI in predicting Group C CAD i.e with 
gensini score ≥ 33 was studied using ROC plot. The results showed that HOMA-IR 
has sensitivity of 85 % and specificity of 66 % for predicting group C CAD while 
QUICKI index has sensitivity of 87 % and specificity of 67.5 %. In the study group 
HOMA-IR in CAD population was further studied in presence of all the risk factors 
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which are directly or indirectly associated with coronary artery disease. The results 
showed that in presence of other risk factors HOMAI-IR was not statistically 
significant although it increased the risk of CAD 1.2 times. 
Regional fat analysis showed significantly low regional fat (Left arm; right 
arm; trunk; left leg and right leg; head; total fat) in CAD group but the percent fat 
trunk-leg ratio and trunk-limb ratio showed significantly higher values in CAD 
group . 
 
Conclusion: 
On the basis of results from this study it can be concluded that insulin resistance is 
associated with severity of coronary artery disease even in non diabetic population. 
Inta-abdominal subcutaneous fat association with risk of cardiovascular disease is a 
misconcept. Hence visceral fat should be given more importance in this context. 
Although Trunk-limb fat ratio using DEXA scan can also be used as a predictor for 
cardiovascular disease 
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1. Introduction 
Coronary artery disease (CAD) is one of the leading cause of death worldwide. It 
has been estimated that around seven million people which accounts for ~12% 
every year die from CAD. In the United States, almost 1 million patients per year 
suffer from an acute myocardial infarction (MI). Every sixth man and seventh 
woman in Europe will die from MI (1).  
Approximately 3-4% of Indians in rural areas and 8-10 % in urban areas have 
CAD. The epidemiological data comparing risk of coronary artery disease in Indian 
population with American shows that Indians have a four-fold higher risk of then 
the Americans. The risk of acute coronary syndrome is also higher which is 
reported to be around 50%  in men less then 50 years of age and also 25% of these 
tend to occur at less then 40 years of age. Many of them are reported to be  lean, 
non smokers and vegetarians. 
Coronary Heart Disease prevalence has worsened in India in last few decades. In 
developed countries, prevalence of ischemic heart disease is predicted to rise upto 
30-60% by 2020. On the contrary in developing countries, rates are predicted to go 
up by 120% in women and 137%in men by 2020(2) . 
Type-2 diabetes is one of the important cause of coronary artery disease in both 
developning and developed countries. In diabetes insulin resistance has been 
correlated as an important underlying factor contributing to pathogenesis of CAD. 
Also, elevated levels of insulin and insulin resistance can be detected several years 
prior to the diagnosis of type-2 diabetes(3). Insulin resistance syndrome has been 
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demonstrated to have clear relationship with coronary artery disease in type-2 
diabetes but the data on the association of insulin resistance and CAD in non 
diabetics is obscure(4). 
It is also proven that hyperinsulinemia is closely associated with various other risk 
factors for CAD including hypertension, obesity, dyslipidimia, and sedentary life 
style. Various studies have elucidated that insulin resistance i.e hyperinsulinemia 
promotes atherosclerosis in animals(5)(6). Studies on insulin in past have also 
shown that excess insulin in blood can lead to accumulation of fat which further 
leads to atherosclerosis in blood vessels(7) . 
In various epidemiological studies in past hyperinsulinemia has shown to have 
good association with hypercoagulable state and impaired fibrionolysis which 
further add to higher risk of acute coronary events (8) . 
Various studies on insulin resistance in past in patients with Type-2 diabetes 
mellitus considered insulin resistance as a major risk factor for coronary artery 
disease and cerebro-vascular accidents. But there is little knowledge about its role 
play  and association with coronary artery disease in patients without diabetes (9). 
Hyperinsulinemic euglycemic clamping is ideally gold standard for measurement 
of insulin sensitivity which is usually time consuming and expensive but there are 
various other indices which can be used for measuring insulin sensitivity 
conveniently for epidemiological and clinical studies like homeostasis model 
assessment insulin resistance index (HOMA IR) score and . QUICKI (Quantitative 
insulin sensitivity check index) (10). 
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The severity of coronary artery disease can be assessed by various scores like 
syntax, gensini , CASS, BARI, etc. Gensini score  is generally  most widely used 
for assessment of coronary artery disease severity in epidemiological studies. It 
assisgns a severity score depending on the degree of narrowing and location of 
lesion in coronaries (11). 
Metabolic syndrome which is defined as co-occurrence of three out of five of the 
following conditions: abdominal (central) obesity, elevated blood pressure, elevated 
fasting plasma glucose, high serum triglycerides, and low high-density cholesterol 
(HDL) levels is found to be associated with two to three fold increase in risk of 
death from acute coronary syndrome (12). Epidemiological studies conducted in 
past have shown that increased BMI and waist-hip-ratio are clearly associated with 
metabolic syndrome. Recent studies have shown that intra-abdominal fat mass 
compared to subcutaneous fat is more metabolically relevant as it exhibits more 
catecholamine induced lipolysis and release of fatty acids in circulation (13). 
Hence evaluation of body fat depots which inturn is associated with insulin 
resistance becomes of utmost value in preventing coronary artery disease and 
premature deaths. Dual energy Xray absorptiometry is a known technique which 
accurately detects cross-sectionally masses of discreet fat deposits and provides 
valuable information in respect to prediction of metabolic syndrome / 
hyperinsulinemia.  
There is very little data pertaining to insulin resistance in normoglycaemic CAD 
patients and correlation of the same with severity of coronary artery disease. Also, 
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to the best of our knowledge there is no data in literature pertaining to relationship 
of severity of CAD with regional body fat composition although there are few 
reports suggesting correlation of body fat composition with CVD risk factors. 
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2. AIMS & OBJECTIVES Of Study : 
 Primary Objective 
To estimate insulin resistance and its correlation with severity of Coronary 
Artery    Disease (CAD) in non diabetic adult patients aged 30 years and 
above undergoing Coronary angiography in a tertiary care hospital in India. 
 Secondary Objectives 
c) To evaluate the clinical profile/risk factors in non diabetic CAD and to 
study their association with CAD. 
d) To assess regional body composition of fat via DEXA SCAN(Dual 
energy X-ray absorptiometry) and its correlation with severity of CAD 
in Indian Subjects. 
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3. Review Of Literature 
 
3.1 Epidemiology  
Cardiovascular disease (CVD) in current era accounts for nearly 50% of non 
communicable diseases. Worldwide, CAD is the leading cause of death, accounting 
for 17.3 million deths per year which is further expected to grow > 23.6 million by 
2030(14). Interestingly population group affected are those in low and middle 
income countries and most deaths (80%) occur at young age as compared to high 
income groups. Over seven million people every year die from it, accounting for 
12.8% of all deaths. In the United States, almost 1 milllion patients per year suffer 
from an acute myocardial infarction (MI). Every sixth man and seventh woman in 
Europe will die from MI(14). 
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Cardiovascular disease accounts for 10% of disability-adjusted life years (DALYs) 
lost in low-middle income countries and 18% of disability adjusted life years in 
high income countries.  
The burden of cardiovascular disease on both family and society is directly related 
to both loss of productivity and income of the person who is suffering from this 
disabling disease and also of the caretaker, who might have to stop working for the 
care of the patient. In developing countries, this economic burden  further multiplies 
where cardiovascular disease affects mainly working age group population(15). 
                                   
The epidemiological data from global burden of disease study shows that in the year 
1990 developing countries contributed 3.5 million deaths of total number of 6.2 
million deaths. The study further estimated these countries will further account for 
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7.8 million of 11.1 million projected deaths due to coronary artery disease in 
2020(16). 
Worldwide prevalence of obesity (BMI ≥30) doubled from 1980 to 2008 and it is 
estimated that around 2.8 million deaths per year are associated  with either 
overweight or obesity. The American population has the highest prevalence of 
overweight (62%) and obesity (26%)(14). 
The epidemiological data comparing risk of coronary artery disease in Indian 
population with American shows that Indians have a four-fold higher risk of than 
the Americans. The risk of acute coronary syndrome is also higher which is 
reported to be around 50%  in men less then 50 years of age and also 25% of these 
tend to occur at less then 40 years of age. Many of them are reported to be lean, non 
smokers and vegetarians. 
Epidemiological data from National commission on macroeconomics and health 
reports that 62 million people in India are supposed to have CAD by 2015, of which 
23 million of are under 40 years of age(17). The explanation for worsening 
incidence of CAD is because of rapid urbanisation which reflects in lifestyle 
changes that includes diet, sedentary work habits, alcohol intake, and associated 
increase in obesity and diabetes mellitus.  
As per recent data available prevalence of coronary heart disease has been reported 
to worsen in India.Coronary Heart Disease prevalence has worsened in India in last 
few decades. In developed countries, prevalence of ischemic heart disease is 
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predicted to rise upto 30-60% by 2020. On the contrary in developing countries, 
rates are predicted to go up by 120% in women and 137%in men by 2020(18). 
The cardinal features of CAD in India as  compared to other population in world 
(19): 
a) Higher rates High prevalence and   incidence  of hospitalization and 
mortality. 
b) Greater prematurity 5-10 fold more risk of myocardial infarction and 
death in<40 years and 5-10 years earlier onset of the disease. 
c) Greater severity multi-vessel involvement commonly seen. Even not 
uncommon among young premenopausal women. 
d) Lower prevalence of conventional risk factors of coronary artery disease 
like hypertension, obesity, smoking 
e) Higher prevalence of diabetes mellitus, glucose intolerance and other 
inflammatory markers like CRP. Lipoprotein A, homocysteine and 
apoprotein B are also commonly found at higher levels in Indian population. 
f) High proportion of unstable or vulnerable plaque. 
Factors contributing to acceleration of coronary artery disease epidemic in India in 
current era are: 
(i) Demographic transition i.e with increased life expectancy there occurs increase 
in number of old age population. 
(ii)In India, both conventional and non-conventional risk factors play equivalent 
role in CAD. Conventional factors which includes hypertension, diabetes mellitus, 
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dyslipidaemia, smoking, etc are increasing because of  growing urbanization and 
western 'acculturation' in Indian population. Non-conventional risk factors which 
includes hyperinsulinaemia, lipoprotein A, hscrp, etc are determined by underlying 
genetic factors.  
Higher prevalence of these risk factors clearly explains malignant and precocious 
nature of coronary artery disease. 
(iii) Barker’s Hypothesis : Implicates correlation between low birth weight and 
higher likelihood of coronary artery disease in adult life. 
Multiplicative effects of above mentioned conventional and new emerging risk 
factors clearly explains the increasing  burden of coronary artery disease  among 
Indian population, where even some are lean, non-smokers, vegetarian, yoga guru 
and marathon atheletes. 
3.2  Insulin resistance  
 
Type-2 diabetes is one of the important cause of coronary artery disease in both 
developning and developed countries. In diabetes insulin resistance has been 
correlated as an important underlying factor contributing to pathogenesis of CAD. 
Also, elevated levels of insulin and insulin resistance can be detected several years 
prior to the diagnosis of type-2 diabetes(3). Insulin resistance syndrome has been 
demonstrated to have clear relationship with coronary artery disease in type-2 
diabetes but the data on the association of insulin resistance and CAD in non 
diabetics is obscure(4)(20). 
 14 
 
Insulin resistance signifies impaired biological response of tissues to insulin. It is 
seen that during 
initial stages of insulin resistance there occurs compensatory rise in plasma insulin 
levels (hyperinsulinemia) due to biological resistance of insulin at some tissue. This 
may also lead to overexpression of actions in tissues that has normal or mildly 
impaired sensitivity to insulin action.  High levels of insulin act on tissues via 
insulin-like growth factor I (IGF-I) receptor(21). So the resistance to some 
biological effects of insulin with concurrent aggravation of other effects leads to 
various clinical manifestations and sequelae which are collectively defined as  
insulin resistance syndrome(22)(23). 
 
3.3 Mechanisms of Insulin Resistance 
 
Resistance to biological effects of insulin can occur at three levels prereceptor, 
receptor, or postreceptor. Biological effects of insulin and insulin growth factor-1 
(IGF-1) are operated by Phosphatidylinositide 3-kinase (PI3 -kinase) system  
pathway. When insulin and IGF-I binds to receptors on body tissues, beta subunit of 
the receptor undergoes autophosphorylation. This than mediates interaction 
between the receptor and other cell proteins. This results in Phosphorylation of cell 
protein which are tyrosine residues, known as insulin receptor  substrate-1 (IRS-1). 
Further biological effects of insulin are controlled by IRS-1 which is a docking 
protein . IRS-1 binds to the enzyme PI3 –kinase and executes further insulin action. 
PI3 kinase is an important cellular enzyme system which consists of two subunits 
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p85 regulatory subunit and a p110 catalytic subunit. Levels of PI3 kinase are 
regulated by insulin and IGF-I which stimulates increase in concentration of both 
PI3 -kinase and insulin receptor substrate-1 (IRS-1). Activation of this enzyme is 
executes biological effects of insulin in cardiovascular (CV) tissue as well as other 
non cardiovascular tissues. Thus any interference or interaction in the proposed 
pathway of insulin ultimately leads to resistance to the actions of insulin/IGF-I. 
Biological effects such as stimulation of nitric oxide (NO) production from vascular 
endothelium; cation transport mechanism in cardiovascular tissuses and glucose 
uptake in muscle and adipose tissues of body are effected. PI3-kinase enzyme 
system increases NO release, Na pump, K channel, and calcium (Ca) myofilament 
sensitivity. Hence any interference in generation / activation of PI3-kinase will 
finally result in resistance to action of insulin and insulin growth factor-1(24)(25).          
 
 
                                 Diagram showing effect of insulin & IGF-1 
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3.4  Insulin resistance and Dyslipidaemia : 
 
 Resistance to action of insulin in adipose tissuses is the inciting insult which leads 
to increased intracellular hydrolysis of triglycerides (TGs) followed by excess 
release of fatty acids into circulation(26). Moreover, this insulin resistance 
mechanism in fat cells results due to interaction of multiple defective genes which 
pressurises these cells to store more energy. Hence fat cells are not able to fulfil 
demand of body when its needed. Indeed, hypertriglyceidemia occurring due to 
insulin resistance moves to and fro between liver cells and fat cells, where very low 
density lipoprotein (VLDL) and free fatty acids (FFAS) act as ping-pong balls and 
helps to carry energy back and forth between them. Advanced stages of this 
imbalance characterised by marked insulin resistance and dyslipidemia manifest as 
lipodystrohy. Hence, correlation between insulin resistance / hypertriglyceridaemia 
and obesity seems to be  parabolic i.e when the levels of fat in body are either very 
low or very high the movement of fatty acids to the liver increases. This increase in 
flux of fatty acids finally leads to  increase in synthesis and release of VLDL in 
blood (27). 
Different genes have been studied in past that are involved in increased transport of 
fatty acids from peripheral adipose tissuses to liver. Some of them are as: hormones 
inducible lipases, lipoprotein lipase, and C3a complement protein, as well as others 
involved in synthesis of fatty acid transport and binding proteins. Various studies in 
past have shown links between above mentioned lipases but none of these provide 
definite of association of these proteins/genes to obesity syndrome / insulin 
resistance syndrome(28)(29). An important  animal study (mice)  was conducted in 
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past where effect of ASP gene deletion gave shocking contradictory results of lipid 
metabolism (30). High levels of plasma FFAs and hypertriglyceridemia in mice 
with null mutation in fatty acid metabolising protein (CD 36) further indicate’s the 
impaired liver response to the fatty acid flux from peripheral tissues(30). It was also 
found that these mice (null mutation in CD36) were not insulin-resistant. On the 
contrary these mice were more insulin-sensitive which could be explained possibly 
due to diminished uptake of fatty acids by muscle. This hypothesis was further 
supported as transgenic mice overexpressing CD36 in muscle had very low levels 
of fatty acids and triglycerides in blood but were found to be insulin 
resistant(31)(32)(33). 
 
 
3.5 Free Fatty acid transport and VLDL/Triglyceride synthesis:  
 
According to available data free fatty acid in blood is associated with synthesis and 
release of VLDL by the liver. The synthesis of ApoB in body is regulated 
physiologically in the later stage of genesis by the levels of core lipids and the 
adequate functioning of microsomal triglyceride transfer protein (MTP). In the 
abscence of adequate core lipids and/or adequate MPT activity these newly formed 
apoB are not taken up by the endoplasmic reticulum. Hence these further undergo 
early posttranslational ubiquitination which is then degraded by the available 
proteasomes (34). In accordance to this model other studies also link increased 
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synthesis and secretion of VLDL in humans to increased movement of free fatty 
acids from peripheral adipose tissue (35)(36).  
The effect of hyperinsulinemia in the synthesis and release of VLDL in circulation 
appears  controversial. Based on various in-vitro models increased levels of insulin 
for short period is associated with both increase in synthesis of triglyceride and 
inhibition of apoB secretion. Inhibiton of ApoB secretion is correlated with 
posttranslation degradation pathway involved in clearing of defective ApoB in 
body. When the cells were further incubated for longer duration under high 
concentrations of insulin it was seen that VLDL synthesis and secretion increased 
which could be explained because of an insulin-resistant state formed in the cell 
environment after chronic treatment with high insulin levels. Recently conducted in 
vivo human studies, using  hyperinsulinemic clamp technique further support the 
concept of acute inhibitory function for hyperinsulinemia (37). So it can be 
concluded that persons with diabetes mellitus and obesity are resistant to actions of 
insulin (38). 
The important role of apoCIII gene along with the action of insulin in controlling 
levels of plasma triglycerides (TG) was also elucidated in various in-vitro models. 
ApoCIII gene regulates the action of lipoprotein lipase on VLDL and data from past 
studies show that apoCIII-overexpressing transgenic mice have severe 
hypertriglyceridemia which explains important inter-play of insulin and apoCIII 
gene.  
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Diagram explaining interplay of insulin resistance in development of  
Dyslipidemia  
 
 
3.6 Insulin resistance and its role in dyslipidaemia and cardiovascular disease:  
 
The available data from various epidemiological studies suggest that, adequate 
levels of insulin in body prevent excess lipid oxidation and the synthesis and release 
of VLDL is regulated by free fatty acid flux. Hyperinsulinemia denotes presence of 
underlying insulin resistance, rather than contributing to this process. The 
mechanism for increase in free fatty acid translocation is oligogenic and the 
pathway of dyslipidaemia initiates once the production of VLDL from liver is 
increased. Cholesterol ester transfer protein (CETP) plays an important role in 
further increasing serum levels of HDL and LDL (small dense particles)(39). CETP 
in further dyslipidaemic cascade transferes VLDL triglyceride to HDL in return of 
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HDL cholesteryl esters. This resulting TG loaded HDL is then acted upon by 
hepatic lipase which results in generation of smaller HDL particles. Small dense 
LDL is also generated after hydrolysis of CETP induced LDL-TG.  
Since both insulin resistant individuals without diabetes and patients with diabetes 
do not have higher levels of low density lipoprotein (LDL) Cholesterol, the 
increased cardiovascular risk in them can be explained as: 
1. The concentration of VLDL particles in insulin resistant individuals is high 
which in prescence of CETP (cholesterol enhanced transport protein) receive high 
cholesteryl esters from HDL and LDL. These VLDL particles are thus able to 
deliver more cholesterol per particle to the vessel wall(40)(41). 
2.  Decrease in levels of high density lipoprotein (HDL) cholesterol and apoA-I  
means  that fewer particles are involved in cholesterol efflux from peripheral 
tissues, which is  the prime step in reverse cholesterol transport(42). 
3.  Fewer HDL particle means direct antiatherogenic actions of HDL on the vessel 
wall are not fulfilled, including the role as an antioxidant. Scavenger receptor B1 
(SRB1) which was studied in past by Krieger etal(43), was demonstrated to deliver 
HDL cholesterol esters to the liver (delivery of core lipid by the HDL particle 
without endocytosis and degradation of the whole particle), targeting that 
cholesterol for excretion via the biliary pathway. Hence low levels of HDL which 
also denotes underlying insulin resistance could be explained by increased SRB1 
gene expression(44). 
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4. Finally the increased concentration of small dense LDL may be more atherogenic 
than an equal number of cholesteryl ester–rich large sized LDL, because small 
dense LDL are more liable to oxidation and more capable of penetrating and 
sticking to the ECM (endothelial cell membrane) of the artery wall(45)(46). 
3.7 Insulin resistance and hypertension:  
Although association of insulin resistance with hypertension is not as common as 
compared to dyslipidaemia but certainly prescence of hypertension significantly 
increases the risk for cardiovascular disease if present(47). The correlation of 
insulin resistance which has been grossly studied and defined for dyslipidaemia is 
not available for hypertension and insulin resistance. Although data from 
epidemiological studies in past show that high blood pressure and high insulin 
levels are independently associated . As per data available to date insulin resistance 
is demonstrated to be present in about 50% of subjects with hypertension(48). 
The association of hypertension and insulin resistance has been proposed due to 
underlying defect in vasodilation (endothelial function defect) and altered blood 
flow pattern. 
Studies on humans have demonstrated that Insulin has vasodilatory effect in normal 
individuals. Importantly this effect is found to altered in obese, insulin-resistant 
subjects and also in diabetics(49). Baron etal demonstrated defective production 
and release of nitiric oxide (NO) from vascular endothelium in diabetics. 
Interestingly, increased concentration of plasma FFAs (seen in insulin resistance) 
also shows altered vasodilatory response of methylcholine (50). 
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Insulin resistance has also been correlated with underlying endothelial dysfunction 
and systemic hypertension. It has been explained that defective vasodilatation in 
small arterioles leads to decreased insulin mediated delivery of glucose to muscle 
tissues which could clearly explain the vicious cycle leading to insulin resistance 
syndrome. The Heart Outcomes Prevention Evaluation (HOPE) Study showed that 
use of angiotensin-converting enzyme inhibitor (ACEI) was associated with 
decrease in reported incidence of new-onset diabetes. This can be very well 
explained by inhibition of vasoconstriction by angiotensin which thus improves 
delivery of insulin mediated glucose to muscle tissues and hence improving insulin 
sensitivity and delaying the onset of diabetes mellitus type 2 (51).  
Other mechanisms proposed in the genesis of hypertension in insulin resistant 
patient : 
a) Increased absorption of sodium and water by tubular cells in the kidney i.e 
volume dependent hypertension(52). 
b) Sympathetic nervous system activity has been found to be overactive in 
insulin resistant patients although it has not been shown to ba primary defect 
in these individuals(53)(54). 
 
 
 
3.8 Insulin resistance and clotting-fibrinolysis: 
 
It has been demonstrated that several factors integral to clotting and fibrinolysis are 
increased in individuals with insulin resistance(55). This includes elevated levels of 
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fibrinogen, factor VII, and PAI-1, etc. Postprandial hyperlipidemia post meal is also 
found to be associated with higher levels of Factor VII in blood suggesting 
increased risk for acute CAD. Work done by Hamsten et al. Suggested plasminogen 
activator inhibitor-1 (PAI-1) to be a marker for increased risk of premature 
CAD(56). Hyperinsulinemia stimulates both hepatic and endothelial cells to release 
more PAI-1 in circulation. Recent studies conducted on incubated  endothelial cells 
with VLDL suggested  the role of VLDL in induction and synthesis of PAI-1(57). 
 
3.9 Insulin resistance and atherogenesis: 
 
As per the above discussion question arises whether hyperinsulinemia per se 
contributes to insulin resistance syndrome or it is the consequence of diminished 
insulin mediated glucose uptake in muscle and hence the marker of insulin 
resistance syndrome. This can explained as: 
1.  Insulin is pemissive to VLDL synthesis and secretion hece leading to 
dyslipidaemia, although it is not involved directly pathophysiologically(58). 
2.  High levels of insulin are found to be directly associated with increased salt and 
water retention. 
3.  High levels of insulin directly impairs fibrinolysis and as per studies can also 
induce synthesis and release of PAI-1(59). 
4.  Importantly insulin resistance do not effect MAP kinase component of insulin 
signaling pathway. This pathway is further involved in stimulation of division and 
migration of vascular smooth muscle cells which explains atherogenecity(60)(61).  
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The result of the United Kingdom Prospective Diabetes Study (UKPDS), concluded 
that treatment of diabetes with insulin and oral hypoglycaemics (sulphonylureas) 
effectively reduced CAD events (P= 0.052). This fact hence disregards the concept 
of direct atherogenic effect of insulin and in turn supports the use of insulin and 
other hypoglycemic agents(62). These clinical data was further weighted by an 
animal study done in cholesterol-fed rabbits. This study showed that administration 
of in-vivo insulin for 24 weeks did not worsen atherosclerosis(63). 
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3.10 Insulin resistance and Vessel wall: 
 
On the basis of epidemiological studies there is enormous data that insulin 
resistance plays an important role in atherogenesis. This was demonstrated in 
Insulin resistance and Atherosclerosis study. In this study association between 
insulin resistance and carotid artery intima/media thickness was studied. The results 
concluded positive correlation  even after adjusting for other associated risk 
factors(64). This also explains the effictiveness of thiazolidinediones in 
ameliorating endothelial dysfunction in individuals with the insulin resistance 
syndrome 
 
.   
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3.11 Estimation of insulin resistance 
Insulin resistance has been studied in detail and has been accepted as major risk 
factor in etiology of diabetes mellitus, hypertension, dyslipidaemia, atherosclerotic 
vascular disease including coronary heart disease and stroke. Hence it becomes 
important to recognize insulin resistance in the pre-disease stage so that adequate 
therapeutic steps can be taken pre-hand before disease manifests. Insulin resistance 
can be measured via several techniques such as: 
 
1. Euglycemic hyperinsulinemic clamp (HEC) technique:  
 
This is the gold standard technique. Hyperinsulinemic Euglycemic Clamp (HIEC), 
which was originally defined by DeFronzo, is currently widely accepted for 
determining metabolic insulin sensitivity in humans(65). After fasting overnight, 
insulin is infused intravenously at a constantrate that usually range from 5 to120 
mU/m2/min (dose per body surface area per minute, during 180 min). This constant 
insulin infusion sets a new steady-state insulin level that is above the fasting level . 
As a result, glucose disposal in skeletal muscle and adipose tissue is increased 
while hepatic glucose production (HGP) is suppressed. Under this steady state, a 
glucose analyzer is used to frequently monitor blood glucose levels at 5–10 min 
intervals, while 20% dextrose is given simultaneously at a variable rate in order to 
“clamp” blood glucose concentrations in the normal range (euglycemic). Soon 
steady-state level is achieved for plasma insulin, blood glucose, and the glucose 
infusion rate (GIR). During this hyperinsulinemic state there is no change in levels 
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of blood glucose  under steady-state clamp conditions, hence the glucose infusion 
rate is equal to the glucose disposal rate (M) by the body. Thus body glucose 
disposal rate at a given level of hyperinsulinemia can be directly determined. 
Alternatively, an insulin sensitivity index derived from clamp data which is defined 
as S.I = M ∕G× ∆ I , where M is normalized for 
G (steady-state blood glucose concentration) and ∆I  is the difference between 
fasting and steady-state plasma insulin concentrations(66)(67). 
 The validity of HEC measurement of insulin sensitivity depends on achieving a 
steady-state condition which is defined as  a period more than 30 min (at least 1 h 
after initiation of insulin infusion) during which the coefficients of variation for 
blood glucose, plasma insulin, and GIR are less than 5%(68).  Radiolabeled glucose 
tracer during hyperinsulenemic clamp conditions can also be used to determine 
synthesis of hepatic glucose, which can be used to correct glucose disposal rate (M) 
in the event when hepatic glucose production cannot be fully suppressed (69). 
The favouring point of the glucose clamp technique in human beings is that it can 
directly express whole body glucose disposal rate at a certain level of 
hyperinsulinemia under steady-state conditions. HEC technique ideally should be 
used in all research settings where determining insulin sensitivity is utmost 
important and feasibility is not a problem. 
The main limitations associated with this approach includes: it is time consuming, 
comparatively expensive, more laborious, and needs high expertise for technical 
issues. Another hurdle in this technique is that it utilizes steady-state insulin levels. 
This levels of insulin are basically supraphysiological which then results in a 
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reversal of the normal portal to peripheral insulin gradient. Therefore application of 
this technique does not actually determines normal physiological dynamics of 
glucose and insulin(70)(71). In this technique insulin sensitivity is measured only 
under a steady-state condition which does not take into account dynamic conditions 
such as those occur physiologically after normal meals. Nevertheless, it is important 
to note that the HEC measures insulin-stimulated glucose disposal only at insulin 
levels in the upper physiological range; hence  information provided on the effects 
of insulin on glucose uptake and production in the basal condition, which is 
physiologically more important, is not provided (72)(73). 
 
2. Insulin tolerance test: 
 
Insulin tolerance test was the initial test studied for determining insulin sensitivity 
in vivo. After fasting overnight a fixed bolus of regular human insulin (0.1 IU/kg ) 
is given iv. Blood samples collected at 15 and 5 min before and 3, 6, 9, 12, 15, 20 
and 30 min after insulin injection, and the fall in plasma glucose is then measured. 
Intravenous glucose is later given at 30 min to stop further decrement in plasma 
glucose(74). The faster the fall in glucose concentration, suggests that the subject is 
more sensitive to insulin. This slope of the linear fall in plasma glucose level 
(KITT) can be derived by dividing 0.693 by the plasma glucose half-time (i.e 50% 
from baseline): 
 
                           KITT =  0.693 / t1/2  x 100 
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where t1/2 is the half-life of plasma glucose fall, and it is derived from the slope of 
least square analysis of the  glucose concentrations from 3 to 15 min after 
intravenous insulin injection, when the plasma glucose level declined linearly. 
Normal KITT value is commonly 2.0%/min and values <1.5%/min is considered 
abnormal. This method is an indirect estimate of overall insulin sensitivity(75). 
 
3. Insulin Suppression test 
 
This is another method that directly measures metabolic insulin 
sensitivity/resistance, was defined by Shen et al. in 1970 and subsequently modified 
by Harano et al(76)(77). Somatostatin (250 mg/h) or Octreotide (25 mg bolus, 
followed by 0.5 mg/min) is given intravenously, to suppress endogenous secretion 
of insulin and glucagon. Insulin (25 mU/m2/min) and glucose (240 mg/m2/min) are 
than infused over 3 h. Blood samples are than analysed for glucose and insulin 
every 30 min for 2.5 h, and then at 10 min intervals from 150 to 180 min of starting 
insulin suppression test. This constant infusions of insulin and glucose helps to 
determine steady-state plasma insulin and glucose concentrations. Steady-state 
period is usually assumed to be from 150 to 180 min from initiation of test. Steady 
state plasma insulin levels are usually similar among subjects but steady state 
plasma glucose concentrations are higher in insulin resistant subjects i.e  SSPG 
values is inversely correlated to insulin sensitivity(78). 
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4. Oral Glucose tolerance test 
 
Oral glucose tolerance test is a commonly used and simple test in routine clinical 
practice to diagnose glucose intolerance (79)(80). Blood samples of patients are 
analysed after overnight fasting, for glucose and insulin concentrations at 0, 30, 60, 
and 120 min after a standard oral glucose load (75 g). Diabetes is defined as plasma 
glucose level ≥200 mg/dl (11 mmol/l) as measured 2 h after the ingestion of a 75 g 
glucose load. The glucose level in range of 140–199 mg/dl (7.7–11 mmol/l) 2 h 
post-glucose load is defined as impaired glucose tolerance(81). Oral glucose 
tolerance thus reflects the efficiency of body to handle glucose after an oral glucose 
load. 
This test has few limitations which make it less desirable for inclusion in research 
studies (82)(83). 
1. The rate of gastric emptying and glucose absorption from intestine is highly 
variable therefore time of start is imprecise due to which reproducibility of 
results tend to be poor.  
2. This test does not adequately define the dynamics of glucose and insulin 
action.  
 
Therefore OGTT becomes a relatively crude measure of glucose tolerance 
which does not measure the components of insulin sensitivity and insulin 
secretion(84). 
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5 .The homeostasis model assessment insulin resistance index (HOMA IR) 
score:  
Insulin resistance derived from fasting glucose and insulin concentration shows 
hepatic insulin sensitivity and basal hepatic glucose production. 
Matthews et al in 1985 proposed a computer model using insulin-glucose 
interactions called homeostasis model assessment(85). The homeostasis model 
assessment insulin resistance index (HOMA IR) evaluates resistance via calculation 
from fasting insulin and glucose concentrations.This model assumes that normal-
weight healthy subjects aged <35 years have 100%  Beta cell function and insulin 
resistance of 1. Correlation of this model with hyperinsulenemic euglycaemic 
clamping was reported to be 0.88; p<0.0001(Matthews et al. 1985) and 0.59; 
p<0.0005(Stumvoll et al.2000)(86). Matsuda and DeFronzo in 1999 studied the 
inverse value of HOMA with HEC in subjects with normal glucose tolerance (0.65; 
p<0.0001), insulin resistance syndrome (0.56; p<0.0001) and in patients with 
diabetes (0.51; p<0.0001)(87). 
The equation suggested by Matthews et al : 
 
◦ International Formula:  fasting Glucose(mmol/L) x fasting Insulin(mU/L) / 
22.5  
 
◦ US Formula:  fasting Glucose(mg/dl) x fasting Insulin(µU/mL) / 405 
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6. QUICKI (Quantitative insulin sensitivity check index):  
This is another empirically derived mathematical formula that uses fasting blood 
glucose and plasma insulin concentrations to determine insulin resistance. It is an 
important reliable and reproducible index of insulin sensitivity with high positive 
predictive value. As levels of serum fasting insulin have a non-normal skewed 
distribution so log transformation of it improves its linear correlation with reference 
standard glucose clamp method (HEC).Katz et al.2000. QUICKI is calculated as: 
       
QUICKI = 1 / (log(fasting insulin µU/mL) + log(fasting glucose mg/dL) 
As an easy, highly reproducible surrogate for HEC-derived insulin sensitivity, 
QUICKI can be considered as an appropriate and effective index of insulin 
resistance for use in epidemiological/ research studies(88)(66). 
 
Both QUICKI and HOMA indices were derived in a completely different 
conceptual fashion. Nevertheless, both idices are mathematically correlated to each 
other, i.e., QUICKI is proportional to 1/log(HOMA)(89).  
The major advantage of these indices is that both can be assessed by only one 
sample of blood drawn from a fasting patient; hence extensive labour , cost and 
technical expertise can be avoided.  
However, the important disadvantage with both these indices was that both these 
indices fail to provide information about the stimulated glucose and insulin levels. 
These tests thus provide  information only about what is occurring with homeostatic 
mechanisms in the fasting state i.e about the  insulin action on hepatic glucose 
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production and not on peripheral glucose uptake, which is comparatively the more 
important and crucial aspect of insulin resistance. 
The reported values of QUICKI were 0.382+/-0.007 for non obese, 0.331+/- 0.010 
for obese and 0.304+/-0.007 for diabetic individuals. QUICKI index was correlated 
with HEC with correlation coefficient 0.78 ;  p<.000. 
7.  Other insulin sensitivity indices: 
Cederholm index: This index reflects peripheral insulin sensitivity and glucose 
uptake in muscle tissues; as the peripheral tissuses are dominantly involved in 
glucose disposal after an oral glucose load(90). 
ISIcederholm =  75000 + (G0 – G120)x1.15x180x0.19x m  / 120xGmean xlog(Imean) 
Where:   75000 is oral glucose load in OGTT 
G0 is fasting glucose in mmol/l 
G120  is plasma glucose in 120th min 
1.15 is the factor transforming whole venous blood glucose to capillary values 
               m is the body weight  
                Imean is the mean plasma insulin 
                Gmean is the mean plasma glucose concentration 
McAuley index: This formula was proposed for calculating insulin resistance in 
normoglycaemic individuals. Regression analysis was done to calculate cutoff 
points. Bootstrap procedure was used to find a index which more strongly correlates 
with insulin sensitivity corrected for fat free mass obtained by HEC(Mffm/I). The 
combination of fasting insulin levels and triglycerides were  used in the formula as: 
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Mffm/I = e2.63−0.28 ln (I0)−0.31 ln (TAG0) 
 
Matsuda Index: It uses both hepatic and peripheral tissues insulin sensitivity. This 
formula consider plasma glucose and insulin in both fasting and during OGTT. 
 
  
3.12 Dual energy X-ray absorptiometry : 
Epidemiological studies showed that the regional distribution of fat is associated 
with various metabolic complications considered to be risk factors for 
cardiovascular disease(91). Studies in past also showed that more amount of intra 
abdominal fat is related to cardiovascular disease as it is more lipolytic; hence 
leading to increased flux of fatty acids into the circulation. Increased flux of fatty 
acids is further associated with increased triacylglycerols hepatic synthesis which 
sets in stage for proatherogenic mileu. Association of Other regional fat distribution 
with cardiovascular disease has not been studied extensively. CT scan was 
proposed previously to look for intra abdominal and subcutaneous distribution of 
fat(92)(93). 
Recent advances in X-ray field led to development of DEXA scan which has the 
unique ability to measure bone mineral content and also regional body fat (non-
bone lean mass) components  i.e  upper limbs, lower limbs, and trunk. Although it 
cannot distinguish between intra abdominal fat and sub-cutaneous fat, it is the 
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cheapest available tool to study fat distribution and even exposes to smaller doses 
of radiation than CT or MRI do. There are also several cross-sectional studies that 
showed an association between regional body composition, especially trunk-lower 
limb fat ratio measured by dual-energy X-ray absorptiometry  (DEXA), and several 
cardiovascular disease risk factors(94)(95). Interestingly, reports from some DEXA 
studies show that peripheral fat is negatively associated with metabolic dysfunction 
in postmenopausal and elderly women(96). 
Dual X-ray absorptiometry (DXA), also known as densitometry can distinguish 
different body structures. Axial bone densitometry of the lumbar spine and hip is 
the modality most commonly used in clinical practice for BMD. The available 
DEXA systems include different types of hardware (filters, collimators, detectors) 
and software (analysis algorithms).The X-ray source can emit a pencil-beam 
(pinhole collimator), which is registered by a single detector, or a fan beam (slit 
collimator), which is registered by a multiple detector. The latter system reduces 
the acquisition time and improves image quality. At the same time, the analysis 
algorithm discriminate bone from soft tissue in a variable way(97)(98)(99). 
METHODOLOGY: The patient lies supine, centered on the table with the arms 
along sides of the body, hands facing the legs without touching them and the 
thumbs up . Following the acquisition, two images of the whole body are obtained, 
one of bones and other of soft tissues . The region of  interest correspond to 
anatomic regions: the head up under the chin; arms separated from the body with 
the cut lines passing through the armpits; forearms separated from the body, legs 
separated from the arms and the medial cut lines located between both legs; the 
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limits of the spine are adjacent to it, on both sides; pelvis: the upper cut line 
located immediately above the pelvis and cut lines through the femoral neck 
without touching the pelvis . Automatically analysis is done for regional body fat  
in Grams as well as  percentage of total body fat(100). 
 
3.13 SEVERITY OF CORONARY ARTERY DISEASE               
Severity of coronary artery disease can be assessed on the basis of various 
formulated scoring systems.  In 1975 Gensini et al defined a scoring system for 
severity of CAD based on number of diseased coronary arteries, localization of the 
diseased segment, and the grading of stenosis. This score estimates severity of CAD 
as: 
 Stenosis of the lumen of the coronary artery is graded as: 
 1 for ≤25% narrowing, 2 for 26-50% narrowing, 4 for 51-75% narrowing, 8 
for 76-90% narrowing, 16 for 91-99% narrowing, and 32 for total occlusion. 
 After estimating the initial score it is multiplied by a constant based on the 
position of the lesion in the coronary arterial tree i.e: 5 for the left main 
coronary, 2.5 for proximal left anterior descending artery, 2.5 for proximal 
left circumflex artery and 1.5 for mid-region of LAD, 1 for the distal left 
anterior descending artery and 1 for mid-distal region of the left circumflex 
artery  and 1 for lesion in any segment of right coronary artery.Final Gensini 
score is expressed as the sum of the scores for all diseased segments in all 
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three coronary arteries (including multiplication with the constant describes 
as above)(101).  
The extent of coronary artery disease can be further subclassified into low, 
moderate and severe. 
 
 Low gensini score        = 1- 14 
 Moderate gensini score = 15 -32 
 Severe gensini score   =    ≥33 
 
Calculation of Gensini score 
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There is very little data pertaining to insulin resistance in normoglycaemic CAD 
patients and correlation of the same with severity of CAD. To the best of our 
knowledge there is no data in literature pertaining to relationship of severity of 
CAD with regional body fat composition although there are few reports suggesting 
correlation of body fat composition with CVD risk factors. 
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4.1 Study Setting / Design: 
 This single centre prospective observational study was conducted on 
consecutive non diabetic patients aged 30 years and above, admitted for 
coronary angiography in the general and private wards of Department of 
Cardiology from August 2013. A detailed history and physical examination 
pertaining to cardiovascular system was performed. All routine blood 
examination, ECG, Chest X-Ray, BBVS was done. 
 
 After taking informed-written consent, samples of blood for fasting/postprandial 
blood sugars, HbA1C/ Insulin assay was sent in all subjects prior to being 
posted for Coronary angiogram. Insulin resistance (by HOMA-IR Score and 
QUICKI index) was than calculated in all subjects. Coronary Angiograms were 
performed in our cardiac cathlab via radial / femoral route using Philips Allura 
Clarity FD10 and Philips Allura Xper FD10 cath machines. DEXA (DUAL 
ENERGY X-RAY ABSORPTIOMETRY) Scan using HOLOGIC (Model-
Discovery-A 83624)-Software 13.4.2/3 was also done prior coronary angiogram 
to assess regional distribution and total body composition of fat in all patients. 
 
 Angiographic data of all study patients was than reassessed and severity of 
coronary artery disease was calculated with help of Gensini Score. Patient with 
normal epicardial coronaries was designated as NON CAD (Gensini score=0) 
and those with minor, single or multi-vessel coronary artery disease were 
designated as CAD (Gensini score>1). CAD group was further subdivided into 
3 groups: 
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 Group A - Gensini score 1- 14 
 Group B – Gensini score  15 -32 
 Group C - Gensini score  ≥33 
 
 Angiographic data was than correlated with insulin resistance scores (HOMAIR and 
QUICKI). CAD group acted as cases and Non CAD group as controls.  
 
 Correlation between clinical profile of non diabetic CAD and presence or absence of 
insulin resistance was also assessed. 
 
 Regional fat distribution via DEXA was also correlated with levels of insulin resistance 
and CAD and non CAD status.  
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4.2   Detailed diagrammatic Algorithm of the study  
 
 
4.3   Study Period: 
August 2013  -  December 2014 
 
 
 Adult patients (30 to 80 years) undergoing 
CAG 
EXCLUSION CRITERIA: 
 Recent Acute MI 
 Not willing for participation 
 LV Dysfunction (killip’s >2 post 
MI) 
 Hepatic Failire 
 Vascular Diseases (on 
prednisolone) 
 DM on OHA/Insulin 
 Famililial Hypercholesterolemia 
 Thyroid dysfunction 
 Adrenal dysfunction 
Routine blood investigations (AC/PC/HBAIC/Serum 
Creat/Lipid profile); ECG;C-XRY 
Fasting Serum Insulin on day of procedure 
ENDPOINTS: HOMA-IR & QUICKI Score; Gensini 
score (CAG) 
  Correlation of severity of CAD with Gensini score 
  DEXA Scan to look for regional body fat and 
association with CAD 
 
Secondary Endpoints: Regional body fat composition 
via DEXA & its correlation with CAD 
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4.4   Inclusion Criteria: 
 
a) All patients between 30 to 80 years who are referred for Coronary angiogram  by 
the attending physician and who are non diabetics will be included in the study. 
Diabetes mellitus will be defined as per ADA guidelines (HBA1C ≥6.5%; 
FPG≥126 mg/dl; 2h PP ≥200 mg/dl or RBS≥200 mg/dl). 
b) Patient willing to undergo study with signed consent. 
 
4.5   Exclusion Criteria: 
 Recent Acute MI 
 Not willing for participation 
 LV Dysfunction (killip’s >2 post MI) 
 Hepatic Dysfunction 
 Vascular Diseases (On prednisolone) 
 Diabetes Mellitus  
 Familial Hypercholesterolemia 
 Thyroid dysfunction 
 Adrenal Failure,Hypopitutatirism (any cause of hypocortisolism) 
 Serum Creatinine > 1.4 mg/dl 
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4.6   Sample size calculation 
Regression methods - Sample size for correlation coefficient analysis (testing 
against population value) 
 
Sample correlation coefficient  0.35 
Population correlation coefficient  0.1 
Power (1- beta) % 80 
Alpha error (%) 5 
1 or 2 Sided 2 
Required sample size 115 
 
With a power of 80%and alpha at 5% with a 2 sided test we need to study 115 
subjects posted for Coronary angiogram. 
4.7   Method of evaluation: 
1. All patient without diabetes aged 30 - 80 years referred by attending 
physician for coronary angiogram  were personally counselled about the 
study details and if willing for the same were included in the study. 
2. Informed-written consent in patients local language 
(Hindi/Tamil/Telugu/Bengali) was obtained and confidentiality of data 
reassured. 
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3. Complete details of the patient were noted on structured proforma along with 
proper anthropometric measurements. 
4. Detailed analysis of risk factors (smoking/ physical activity/ hypertension/ 
family history/ Ischaemic heart disease/ obesity/ dyslipidaemia/ family 
history/ CKD/ peripheral arterial disease/ CVA history) was done. 
5. Patient was than clinically assessed before commencing for coronary 
angiogram. 
6. Blood samples pre procedure (coronary angiogram) for AC/Hba1c and 
insulin assay were  taken in the ward. 
7. All patients also underwent DEXA scan for regional fat assessment in 
endocrinology department prior to coronary angiogram. 
8. Coronary angiograms of all patient were assessed and gensini score was than 
calculated. 
9. Insulin resistance was derived with fasting blood sugars (AC) and insulin 
levels using HOMA-IR and QUICKI scores. 
10. All patient whose coronary angiogram was reported normal were designated 
as NON CAD (controls) and when coronary angiogram showed minor/ 
single or multi-vessel disease were designated as CAD (cases). 
4.8    Statistical analysis: 
EPIDATA software was used for data entry and analysis of data was done in SPSS 
IBM Statistics 22 software. 
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Comparison of outcome variables were done between cases (CAD) and 
controls(Non CAD) using univariate analysis. After obtaining the significant risk 
factors, Multivariate analysis was done for adjusting the confounding factors 
When the outcome of a continuous variable was within the normal distribution 
(bell-shaped curve), comparison between the groups was done with Independent ‘t’ 
test of significance.  
When the outcome of continuous variable was not within the normal distribution 
(skewed distribution), the comparison was done using Mann Whitney U Test. 
Categorical variables were analysed using the chi-square test of significance to 
analyse the association between the risk factor and coronary artery disease and 
Odds Ratio with 95% Confidence intervals were calculated. 
The significant risk factors were identified and then Multivariate analysis with 
Logistic Regression Analysis was done and results were obtained. 
The CAD population which was sub-divided into 3 groups was further studied for 
significance of Insulin resistance and regional body fat distribution using 
ANNOVA tests.  
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5.  Results: 
5.1 Inclusion of patients and Study flow diagram: 
As per sample size calculation prior to study estimated sample size was 115. In our 
study 116 patients gave written-informed consent for study. 5 patients failed to get 
DEXA scan, 4 patients had inadequate blood samples for insulin estimation and 1 
patient refused coronary angiogram on date of procedure for personal reasons. 
Hence the study protocols were followed and analysed in 106 patients. 
Figure1. Study flow Diagram 
           
  
                                                                     5 patients failed DEXA scan 
                                                                     4 had inadequate insulin samples 
                                                                     1 patient refused coronary angiogram 
 
 
 
 
  
 
116 patient without diabetes 
agreed to participate in study after 
written-informed consent 
106 patients underwent CAG ; blood 
for AC/ Insulin was collected on day 
of procedure; DEXA scan completed 
before CAG 
      CAG assessed for Gensini Score 
Gensini Score=0 (NON CAD) 
                      N=40 
Gensini score= ≥1 (CAD) 
                    N=66 
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5.2  Baseline characteristics: 
In our study after undergoing coronary angiogram 106 cases were subdivided into 
cases (n=66) and controls (n=40) on the basis of gensini scoring. The baseline 
characteristics of both population group was as under: 
 
Table 1 Baseline characteristics  of cases and control (n =106) 
 
VARIABLES CASES N=66 CONTROLS N=40 
AGE 55.30±9.19 51.95±7.94 
SEX 
Male 
Female 
 
57(86.4%) 
9 (13.6%) 
 
22 (55%) 
18 (45%) 
Height 1.61±0.06 1.59±0.08 
Weight 66.37±9.39 62.45±9.7 
BMI 25.41±3.41 24.49±3.22 
Smoking 42(63.6%) 4  (10%) 
Hypertension 40 (60.6%) 9  (22.5%) 
Obesity 37(56.1%) 14 (35%) 
Physical activity 23(34.8%) 25 (62.5%) 
Dyslipidaemia 36(54.5%) 3  (7.5%) 
Family H/O 24(36.4%) 1  (2.5%) 
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CKD 1 (1.5%) 0 
PAD 2  (3%) 0 
CVA h/o 2  (3%) 0 
IHD 4  (6.1%) 1 (2.5%) 
Pulse 77.77±9.31 75±9.00 
Systolic BP 136.82±15.97 122.65±14.5 
Diastolic BP 83.98±10.39 75.12±7.03 
Haemoglobin 13.3±1.41 12.45±1.44 
Creatinine 1.04±0.19 0.93±0.21 
TC 163.08±49.29 155±33.63 
TG 150.53±81.54 134±46.52 
HDL 41.91±12.56 42.8±10.87 
LDL 101.80±39.60 95.08±31.96 
AC 99.20±10.54 97.77±11.21 
PC 114.74±19.67 107.45±14.18 
Hba1c 5.65±0.45 5.51±0.40 
Insulin 9.73±5.83 5.62±4.99 
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Age distribution: The mean ages were almost similar in both cases and controls. 
The mean age among cases was  55.30±9.19 years and mean age among controls 
was  51.95±7.94 years. Hence, it was predominantly a middle aged study 
participants. 
 
Gender Distribution:  In our study group males predominated in CAD group- 57 
(86.4%) as compared to control group -22 (55%). This goes according to the fact 
that male gender is more associated with coronary heart disease. 
 
 
 
Figure 5(a) Gender distribution among cases and control (n = 106) 
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Obesity in study population: Obesity was defined in our study as BMI≥ 25 and 
patients with BMI < 25 were designated as non obese. Our study group showed that 
among 40 non CAD patients 35 % were obese and in CAD group 56 % had obesity. 
 
 
Figure 5(b) Obesity distribution in the study group n=106 
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Hypertension in study group: In the study among 106 patients 9 (22.5%) patient 
in control group and 40 (60.6%) patients in CAD group were hypertensives at time 
of admission. 
 
 
                     
                    Figure 5 (c) Distribution of hypertension in study group 
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Smoking distribution: In the study group of 106 population 42 (63.6%) patients in 
CAD group and 4 (10%) patients in control group were smokers. This result is 
consistent in accordance to  fact that smoking is an important risk factor for CAD. 
 
 
Figure 5 (d) Distribution of CAD populations on the basis of smoking habit. 
 
 
Figure  5 (d) Distribution of Non CAD group on the basis of smoking habit. 
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Dyslipidaemia in study group:  In the study population dyslipidaemia prevailed in 
54.5% of CAD group and 7.5 % in Non CAD group. Dyslpidaemia as well known 
risk factor for CAD was found to be significantly higher among cases. 
 
Figure 5 (e) Dyslipidaemia distribution in CAD population 
 
 
                        Figure 5 (e) Dyslipidaemia distribution in study group 
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Family history of CAD group:  In the study group of 106 patients 24 patient in 
CAD group and 1 patient in Non CAD group gave history of CAD in family. The 
family history for coronary artery disease was considered to be positive if the 
subject gave  history of coronary artery disease in a parent or sibling before 60 
years of age which could be of myocardial infarction, coronary artery bypass 
surgery, angina pectoris, or pathological exercise tolerance test diagnostic of 
ischemia. 
 
 
Figure 5 (f) Distribution of study group on the basis of positive family history 
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Physical Activity:  In the study group 25 patients among 40 patients in Non CAD 
group followed a physically active lifestyle while 23 patients among 66 patients in 
CAD group were physically active while rest 43 patients had sedentary lifestyle. 
 
Figure 5 (g) Distribution of study group on the basis of physical activity 
 
Other risk factors: As in our study most of the patients belonged to stable 
outpatient group hence prevalence of risk factors like cerebrovascular 
accident(CVA), peripheral arterial disease (PAD), and history of ischaemic heart 
disease was low. Therefore correlation of these risk factors among cases and 
controls is not studied. 
Haemodynamic evaluation of study group:  In the study 106 patients were 
clinically examined prior entering into the study. The mean pulse recorded in the 
CAD group was 77 and  in the non CAD group mean pulse was 75. 
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The mean systolic blood pressure in the CAD population was 136.82±15.97mmhg 
and in Non CAD population mean systolic BP was 122.65±14.5mmhg. CAD 
patients had higher systolic mean BP by 44.17 compared to control group. 
The mean diastolic blood pressure in CAD group was 83.98±10.39 mmhg and in 
Non CAD group was 75.12±7.03. CAD patients had higher mean diastolic BP by 
8.86 mmhg. 
Biochemical assessment of study group:   
a) Haemoglobin: In CAD group mean haemoglobin was 13.30 ± 1.41  and in 
the control group was 12.45 ± 1.44  ; haemoglobin was comparable in both 
groups. 
b) Serum Creatinine: In the study mean creatinine in CAD population was 1.04 
± 0.19 and in Non CAD population was 0.93 ± 0.21. The difference in 
creatinine between 2 groups was thus insignificant. 
c) Lipid profile: The mean values of total cholesterol (TC) in CAD group was 
163.08 ± 49.29 mg/dl which was 7.5 mg/dl more than the control group (155 
± 33.63). 
The mean value of triglycerides in CAD group (134 ± 46.52) was found to 
be 16.53 mg/dl higher tha in the control group. 
The mean value of HDL in the CAD population (41.91 ± 12.86) was not 
much different from the non CAD group (42.8 ± 10.87 ) 
The mean value of LDL in the CAD population was 101.80 ± 39.60 mg/dl 
which was 6.72 mg/dl higher than the control group. 
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d)  Blood sugars: In the study mean levels of fasting blood sugar in CAD group 
was 99.20 ± 10.54 mg/dl and non CAD group was 97.77 ± 11.21. Post 
prandial levels of blood sugars were also comparable between two groups 
(CAD- 114.74 ± 19.67 and Non CAD 107.45 ± 14.18) Both groups have 
comparable baseline fasting blood sugars. 
e) Hba1c. The mean Hba1c in the non CAD group was 5.51 ±0.40 and CAD 
was   5.65± 0.47 which were comparable at the baseline. 
f) Insulin levels: The mean levels of fasting insulin in the CAD group was 9.73 
± 5.83 miu/dl and in the control group was 5.62 ± 4.99. Thus the difference 
of 4.11 was noted in the 2 study groups. 
 
5.3 Association of risk factors and CAD in the study group      
In the study 106 patients were assessed for risk factors of CAD before admitting 
them for coronary angiogram through a structured proforma. The various risk 
factors which were elucidated were as : 
1. Smoking habit (current or past)- Study participants who smoked any tobacco in 
the previous 12 months or even took it within the past year were designated as 
current smokers and others who had quit smoking more than a year were included 
in non smoker group. 
2. Hypertension: In the study patient who were already on antihypertensives or 
those who were found to have consistently (>3 readings) high BP (> 140/90) were 
called as hypertensives. 
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3. Obesity: In the study patients with BMI ≥25 were reported as obese. 
4. Physical activity: In the study participants were judged to be physically active if 
they were involved in moderate (walking, cycling, or gardening) or strenuous 
exercise (jogging, football, and swimming) for 4 h or more in a week.  
5. Dyslipidaemia: Participants with history of treatment in past or present for 
dyslipidaemia were included in the group. 
6. Family history:  The family history for coronary artery disease was considered to 
be positive if the subject gave  history of coronary artery disease in a parent or 
sibling before 60 years of age which could be of myocardial infarction, coronary 
artery bypass surgery, angina pectoris, or pathological exercise tolerance test 
diagnostic of ischemia. 
7. Chronic kidney disease: Participants with GFR values < 90 calculated with 
Cockgroft gault formula were designated to have CKD. 
8. Peripheral arterial disease: Patients with h/o claudicating pain or history of 
treatment for the same in past were reported to have PAD. 
9. Cerebrovascular accident : prior history of transient ischaemic attack or CVA 
(ischaemic/haemmoraghic ) 
10. Ischaemic heart disease: In the study patients were judged to have ischaemic 
heart disease if they were on anti-ischaemic medications prior to going for coronary 
angiogram. 
 
 59 
 
Univariate and multivariate analysis were done to assess each of the above 
mentioned risk factors to obtain significant risk factors. The P value with relative 
risk and 95% Confidence intervals are depicted in the Table give below. 
Table 2. Association of risk factors and CAD (Univariate analysis) 
 
Risk Factor Cases Control P value 
Odd’s 
ratio(OR) 
95%Confidence 
Interval (CI)0R 
Smoking 42 (63.6%) 4 (10%) 0.000 15.75 4.996 – 49.657 
Hypertension 40 (60.6%) 9 (22.5%) 0.000 05.299 2.173 – 12.92 
Obesity 37 (56%) 14 (35%) 0.037 2.369 1.05  –   5.33 
Dyslipidaemia 36 (54.5%) 3 (7.5%) 0.000 14.80 4.146 – 52.829 
Physical 
Activity 
23 (34.8%) 25 (62.5%) 0.06 03.116 1.378 – 7.048 
Family history 24 (36.4%) 1 (2.5%) 0.03 22.28 2.877 – 172.648 
Age 66 40 0.062 1.046 .998 – 1.096 
Male sex 57 (86.4%) 22 (55%) 0.001 5.182 2.02 – 13.25 
CKD 1 (1.5 %) 0 (0) 1.000 .000 .000 
PAD 2 (3%) 0 (0) .999 1.010 .000 
CVA 2 (3%) 0 (0) .999 1.010 .000 
IHD 4 (6.1%) 1 (2.5%) .417 2.516 .271 – 23.344 
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In the study of 106 participants all risk factors were assessed individually for the 
risk of CAD. Smoking appeared to be the significant factor for CAD with odd’s 
ratio of 15.75 and 95% C.I 4.99 – 49.65. 
History of hypertension and patients on antihypertensives were also associated with 
significant increase in the risk of CAD; p=0.000 with OR of 2.369 (95% CI 2.173 –
12.92). 
In the CAD population presence of obesity was also significantly associated with 
risk of CAD; p= 0.037 with OR of 2.3 (95% CI 2.173 – 12.92). 
Presence of dyslipidaemia was found to be significantly associated with CAD with 
p value = 0.00 ; OR of 14.80 (95% CI 4.146 – 52.829 ). 
Participants of the study who gave history of physically active life style were not 
associated significantly with reduced risk of CAD; p=0.06. 
In the study male sex and positive family history of CAD were both associated 
significantly (p<0.05) with high risk of CAD. 
The study mainly included the patients getting admitted in daycare ward for 
coronary angiogram hence in this group presence of risk factors like CVA/ CKD/ 
PAD are expected to be low. Therefore in the study these factors are not being 
further analysed. 
5.4  Multivariate analysis and Logistic regression analysis: 
All the risk factors which were statistically significant after univariate analysis were 
further analysed through multivariate analysis and logistic regression model. In this 
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model we also considered age inspite of being insignificant because it’s a well 
known fact that increasing age is an important risk factor for CAD. Insignificance 
in univariate can be explained because of small sample size and case selection from 
outpatient group who are more young and stable. 
 
Table 3 (a): Logistic regression analysis model 
 
Risk Factor P value 
Odd’s Ratio 
(OR) 
95% of  CI 
Age .036 1.067 1.004 – 1.13 
Sex .165 2.295 .711- 7.41o 
Smoker .002 8.341 2.14 -32.50 
Hypertension .273 1.915 .600- 6.117 
Obesity .992 0 .994 0.313 -3.155 
Physical activity  .645 1.297 .430 - 3.192 
Dyslipidaemia .018 5.837 1.351 – 25.12 
Family history .928 .880 .054 – 14.307 
 
Hence after multivariate analysis, the risk factor which were found to be significant 
risk factors are depicted in table 3 b. 
 
 
 62 
 
Table 3(b): Significant risk factors for CAD after logistic regression analysis: 
 
Risk Factor P value Odd’s Ratio (OR) 95% of  CI 
Age .036 1.067 1.004 – 1.13 
Dyslipidaemia .018 5.837 1.351 – 25.12 
Smoker .002 8.341 2.14 -32.50 
 
Hence after multivariate analysis Age, dyslipidaemia and smoking were 
significantly associated with CAD. 
 
5.4 Insulin Resistance (HOMA-IR and QUICKI) and its association with CAD 
In the study blood samples for estimation of fasting insulin and fasting blood sugar 
of 106 patients were taken prior to taking for coronary angiogram. The mean level 
of fasting serum insulin level in the CAD population was 9.73 ± 5.83 µU/ml and in 
control group was 5.62 ± 4.99 µU/ml. 
The mean level of fasting blood sugar in the CAD population was 99.20 ± 10.54 
mg/dl and the control group was 97.77 ± 11.21. 
HOMA-IR was calculated using US formula: 
◦ US Formula:  fasting Glucose(mg/dl) x fasting Insulin(µU/mL) / 405 
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The mean HOMA-IR score in the CAD population was 2.41 ± 1.61 and the mean 
value of HOMA-IR in control group was 1.32 ± 1.13. The p value for significance 
was 0.001; Odds ratio was 2.01 (95% CI 1.35 – 3.01).  
Table 4 (a). Association between HOMA-IR and CAD 
  
 
In the study population insulin resistance was also calculated by QUICKI index 
which is the inverse log of HOMA-IR. 
QUICKI =  1 / (log(fasting insulin µU/mL) + log(fasting glucose mg/dL) 
The mean value of insulin resistance via QUICKI in CAD group was 0.349 ± 0.04 
and the control group the value was 0.395 ± 0.05. This value was also found to be 
significantly associated between two groups (p value < 0.005).  
 
  
 
 CAD NON-CAD 
P Value = 0.001 
OR 2.01 
95% CI: 1.35 – 
3.01 
Mean Fasting Insulin 9.73 ± 5.83 µU/ml 5.62 ± 4.99 µU/ml 
Mean Fasting blood 
sugar 
99.20 ± 10.54 
mg/dl 
97.77 ± 11.21 
Mean HOMA-IR 2.41 ± 1.61 1.32 ± 1.13 
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Table 4(b) . Association between QUICKI and CAD 
 CAD NON-CAD 
P Value < 0.001 
95% CI: 0.026 – 
0.064 
Mean Fasting Insulin 9.73 ± 5.83 µU/ml 5.62 ± 4.99 µU/ml 
Mean Fasting blood 
sugar 
99.20 ± 10.54 
mg/dl 
97.77 ± 11.21 
Mean QUICKI 0.3499 ± 0.04 0.3956  ± 0.05 
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Figure 5(h) . Box plot of the HOMA-IR and QUICKI scores 
 
 
0.34±0.04 0.39±0.05 
2.41±1.61 1.32±1.13 
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 5.5 Correlation between Gensini score and HOMA-IR in the study group 
In the study 66 patients were studied for correlation between insulin resistance and 
severity of CAD via Gensini score. When all participants were analysed in scatter 
plot the correlation coefficient ‘r’ was 0.558 between HOMA-IR and Gensini 
scoring. 
 
 
 
Figure 5 (i). Correlation between Gensini score and HOMA-IR in CAD 
subjects R=0.558 
 
 
 
 r2=0.312 
p=<0.001 
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5.7 Correlation between Gensini score and QUICKI in the study group 
In the study 66 patients were studied for correlation between insulin resistance and 
severity of CAD via Gensini score. When all participants were analysed in scatter 
plot the correlation coefficient ‘R’ was 0.649 between QUICKI and Gensini 
scoring. 
 
Figure 5 (j) . Correlation between Gensini score and QUICKI in CAD subjects 
R=0.649 
  
r2=0.421 
p=<0.001 
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5.7 Association of Gensini score between low and high HOMA-IR groups:  
In our study population cases were further stratified into two groups with low 
HOMA-IR i.e with value <3 and population with high HOMA-IR i.e with value >3. 
The mean gensini score in group with low HOMA-IR score was 37 ± 28 and the 
mean value of gensini score in population with high HOMA-IR value was 83 ± 34. 
The association between two groups was found to be statistically significant 
(p<0.05). 
 
Figure 5(k). Box plot illustrating the comparison of Gensini scores in CAD 
patients with low and high HOMA-IR 
 
P < 0.01 
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5.8 Association between HOMA-IR score and CAD subgroups: 
In the study of 106 participants 66 patients were found to have coronary artery 
disease. This group was than further subdivided into three groups on the basis of 
gensini scoring: 
 Group A - Gensini score  1 - ≤ 14 
 Group B – Gensini score  15 -32 
 Group C -  Gensini score  ≥ 33 
The number of patients in group A were 14 , group B- 6  and group C- 46. The 
mean HOMAIR value in group A was 1.03 ± .78; group B 1.74 ± 0.55   and group 
C was 2.92 ± 1.63. All these groups were analysed using ANOVA which showed 
statistical significance between group A and C (p<0.05) but groups A and B ; 
groups B and C were not significant (p>0.05). 
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Table 6 (a) Mean and standard deviation of  HOMAIR in three CAD 
subgroups 
Groups 
N 
HOMAIR
-Mean 
Std. 
Deviation Std. Error 
95% Confidence Interval 
for Mean 
 
Lower Bound 
Upper 
Bound 
A (GS ≤14) 14 1.0379 .78058 .20862 .5872 1.4886 
B (GS 15 - 
32) 
6 1.7438 .55320 .22584 1.1633 2.3244 
C (GS ≥ 33) 46 2.9235 1.63025 .24037 2.4394 3.4076 
Total 66 2.4163 1.61814 .19918 2.0185 2.8141 
 
Table 6(b) Association between HOMA-IR in three CAD subgroups ( ANOVA 
& BONFERRONI) 
Gensini 
groups  
Mean 
Difference  Std. Error Sig. 
95% Confidence Interval 
Lower Bound Upper Bound 
A B -.70595 .69836 .948 -2.4236 1.0117 
C -1.88560 .43686 .000 -2.9601 -.8111 
B A .70595 .69836 .948 -1.0117 2.4236 
C -1.17965 .62123 .186 -2.7076 .3483 
C A 1.88560 .43686 .000 .8111 2.9601 
B 1.17965 .62123 .186 -.3483 2.7076 
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5.9 Association of HOMA-IR with CAD using Logistic regression and 
Multivariate analysis 
In the study group HOMA-IR in CAD population was further studied in presence of 
all the risk factors which are directly or indirectly associated with coronary artery 
disease. The results showed that in presence of other risk factors HOMAI-IR was 
not statistically significant although it increased the risk of CAD 1.2 times. This can 
easily be explained because insulin resistance signifies underlying metabolic 
syndrome and is not an isolated identity. So, risk factors like obesity, 
dyslipidaemia, hypertension, sedentary lifestyle smoking, etc. leads to metabolic 
syndrome which is strongly associated with CAD. 
Table 7. HOMA-IR Logistic Regression analysis 
Risk Factors P value Odds Ratio 
95% confidence Interval Lower                  
Upper 
Age .065 1.060    .996 1.128 
Sex .197 2.191   .665 7.219 
Smoker .011 6.250    1.510 25.878 
Hypertension .355 1.715    .547 5.378 
BMI .827 .877     .272 2.836 
Physically .985 .988     .305 3.206 
Dyslipidemia .043 4.984    1.049 23.684 
HOMAIR .232 1.285     .852 1.937 
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5.10 Sensitivity and Specificity of HOMA-IR and QUICKI for predicting CAD 
with high Gensini score (≥ 33) 
In our study 66 CAD cases were further stratified into 3 groups as described above. 
Out of these groups sensitivity and specificity of HOMA-IR and QUICKI in 
predicting Group C CAD i.e with gensini score ≥ 33 was studied using ROC plot. 
 
 
 
 
 
 AUC P value 
HOMA-IR 0.832 <0.01 
QUICKI 0.832 <0.01 
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Variable 
Cut-
off 
Sensitivity Specificity PPV NPV 
Positive 
Likelihood 
ratio 
Negative 
Likelihood 
ratio 
HOMAIR 1.60 85 % 66 % 75% 80% 2.6 0.225 
1/QUICKI 2.8 87 % 67.5 % 75.5
% 
82 % 2.68 0.19 
 
Thus we can see that HOMA-IR and QUICKI index have sensitivity of 85% and 87 
% respectively for CAD with high gensini score. The specificity of both tests was 
found to be around 80 %. 
 
5.7 Study of regional fat distribution via DEXA scan in CAD and control 
groups: 
In the study all 106 participants underwent dual energy X-ray absorptiometry scan 
(DEXA scan) prior to going for angiogram. The whole study population was 
divided into CAD (gensini score 0) and Non CAD (gensini score >1). In both 
groups regional subcutaneous fat distribution was studied as under. 
  
 74 
 
Table 7 (a) Regional Subcutaneous fat distribution in CAD and Non CAD 
groups. 
Region 
CASES 
Mean ± S.D 
CONTROL 
Mean ± S.D 
P value 
95% confidence 
interval 
Left arm fat 26.255±8.02 33.128±9.68 .000 3.24 – 10.50 
Right arm fat 26.359±7.96 32.485±9.46 .001 2.55 – 9.69 
Trunk 27.000±7.08 30.772±7.72 .012 .85 – 6.68 
Left leg 25.950±7.76 32.442±8.26 .000 3.33 – 9.65 
Right leg 26.297±7.40 32.390±8.49 .000 2.98 – 9.20 
Head 21.123±2.28 26.308±31.58 .306 -4.9 – 15.30 
Total fat 26.474±6.33 30.848±6.80 .001 1.78 – 6.96 
Percent fat 
trunk-leg ratio 
1.0636±0.15 .9912±0.16 .024 -.13 - -0.009 
Trunk-limb fat 
ratio 
0.260 ± 0.043 0.240 ± 0.05 0.049 -0.03 - - 0.001 
VAT area 117.72±35.69 120.22±31.33 .715 -11.05 – 16.06 
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Regional fat analysis showed significantly low regional fat (Left arm; right arm; 
trunk; left 9leg and right leg; head; total fat) in CAD group but the percent fat 
trunk-leg ratio and trunklimb ratio showed significantly higher values in CAD 
group. The VAT (Visceral adipose tissues area) in two study groups was 
insignificant (p>0.05). This can be explained by the fact that mean BMI of the 
control group was24.49 ± 3.22 which as per the Indian standards is overweight (> 
23). Also this regional fat denotes subcutaneous fat which is less important 
compared to visceral fat. 
 
5.8 Association between Trunk-limb fat ratio in three CAD subgroups: 
As there was significant association between trunk-limb fat in CAD and control 
group; this parameter was further analysed for significance between 3 CAD 
subgroups using ANOVA. This further study showed no statistical significance of 
this parameter in the 3 subgroups (p>0.05). 
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Table 7 (b) Association between Trunk-limb fat  in three CAD subgroups ( 
ANOVA & BONFERRONI) 
The mean value of trunk-limb fat ratio in CAD subgroups was 0.26 ± .03 in group 
A; 0.26 ±.02 in group B and 0.25 ± 0.04 in group C. Further study analysis using 
ANOVA showed no significance between study groups A, B, and C. 
 
 
 
 
 
Gensini 
N 
Trunk-
limb fat 
Mean 
Std. 
Deviation Std. Error 
95% Confidence Interval for 
Mean 
group 
Lower Bound Upper Bound 
A 14 .2652 .03688 .00986 .2439 .2865 
B 6 .2627 .02604 .01063 .2353 .2900 
C 46 .2589 .04711 .00695 .2449 .2729 
Total 66 .2606 .04322 .00532 .2500 .2712 
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Gensi
ni 
group  
Mean 
Difference Std. Error Sig. 
95% Confidence Interval 
Lower 
Bound Upper Bound 
A B .00252 .02138 1.000 -.0501 .0551 
C .00625 .01337 1.000 -.0266 .0391 
B A -.00252 .02138 1.000 -.0551 .0501 
C .00373 .01902 1.000 -.0431 .0505 
C A -.00625 .01337 1.000 -.0391 .0266 
B -.00373 .01902 1.000 -.0505 .0431 
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6. Discussion  
This is the first cross sectional study done in non diabetics to look for association of 
insulin resistance and angiographic severity of coronary artery disease. We also 
looked for demographic characteristics and risk factors for coronary artery disease 
using univariate and multivariate analysis. We included 106 consecutive non 
diabetic patients who were referred for coronary angiogram by the treating 
physician. All patients were routine evaluated and insulin resistance was calculated 
using HOMA-IR and QUICKI index on day prior to angiogram with help of fasting 
blood sugars and fasting insulin levels. Post angiogram patients with normal 
coronaries were  included in control group and patients with coronary artery disease 
(Gensini score ≥ 0) were included in case group.   
Our study noted that risk factors for development of coronary artery disease were 
similar to the traditional risk factors for development of coronary artery disease in 
the general population. As in our study almost all cases were collected from the 
daycare ward so the presence of some risk factors like PAD ; CKD and CVA h/o 
were not reported in the study group; hence were not analysed. 
In our study baseline characteristics of both case and conrol group were studied and 
all the risk factors were analysed using univariate and multivariate regression 
models. 
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6.1 Risk factors and their association with coronary artery disease. 
Age: In our study the mean ages were almost similar in both cases and controls. 
The mean age among cases was  55.30±9.19 years and mean age among controls 
was  51.95±7.94 years. Hence, it was predominantly a middle aged study 
participants. 
On univariate analysis age was found to be associated with risk of coronary artery 
disease p=0.06 (OR 1.046) although not statistically significant which could be 
easily explained because of small sample size. In a large multicentre study on 
15187 patients age-related risk of major adverse cardiac event risk and coronary 
artery disease extent and severity by coronary CT angiography was studied 
(CONFIRM -Coronary CT Angiography Evaluation for Clinical Outcomes: An 
International Multicenter)(102). The results showed that MACCE increased as the 
age advanced. It is a well known fact that as age advances chances of 
atherosclerosis increases along with endothelial dysfunction both of which tend too 
increase risk of coronary artery disease(103). 
Gender: In our study group males predominated in CAD group- 57 (86.4%) as 
compared to control group -22 (55%) p<0.05 (OR=5.1). This goes according to the 
fact that male gender is more associated with coronary heart disease. In an 
important study published by Fadi j charchar et al in 2012; genotypic study on male 
Y chromosome showed significant association with coronary artery diease (104). 
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Another study done for non modifiable risk factors by Taeibi et al in 2014 showed 
that increasing age increases the risk of coronary artery disease and female gender 
are more protected against coronary artery disease(105). 
Obesity: In the present study obesity was defined as BMI≥ 25 and patients with 
BMI < 25 were designated as non obese. The study group showed that among 40 
non CAD patients 35 % were obese and in CAD group 56 % had obesity which was 
statistically significant (p<0.005 ; OR 2.3). Our study was in concordance to 
previous studies which suggest obesity increases risk of coronary artery disease. 
In a large multicentre study done by Troy M Lebountary etal in 2012 on the 
prevalence, severity and risk of coronary artery disease concluded that patients who 
were reffered for suspected coronary artery disease showed that higher BMI was 
independently associated with increased risk of coronary artery disease as well as 
acute coronary events(106). 
Another interesting study assessing the lifestyle and risk factors contributing to 
increased cardiovascular disease in young Indian population was done by Ismail 
etal in 2014 showed overweight and obesity as an important contributor to 
cardiovascular illness(107). 
High prevalence of coronary artery disease in obese individuals can be easily 
explained, to a large extent, by the increased frequency of  well known risk factors 
like hypertension, diabetes, and dyslipidemia. These risk factors either individually 
or as part of the metabolic syndrome play a pivotal role in increasing risk of 
cardiovascular disease . However, obesity is an inflammatory state whichcan itself 
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affect cardiovascular system directly. The inflammatory markers commonly found 
at higher levels in obese individuals are tumor necrosis factor-alpha, interleukin-6, 
plasminogen activator inhibitor-1, resistin, lipoprotein lipase, acylation stimulating 
protein, cholesteryl ester transport protein, retinal binding protein, estrogens, leptin, 
angiotensinogen, and insulin-like growth factor-1 . Thus in view of enough 
evidences obesity can be considered as an important modifiable target to prevent 
risk of coronary artery disease(108). 
Hypertension: In the study among 106 patients 9 (22.5%) patient in control group 
and 40 (60.6%) patients in CAD group were hypertensives at time of admission. 
Thus hypertension was significantly associated with coronary artery disease 
(p<0.05; OR=5.2). This result is in accordance with various studies conducted in 
the past. 
An important study done by Lewington etal in 2002 to look for effect of 
hypertension on vascular mortality showed that with every rise of 20 mm hg 
systolic/10 mm hg diastolic blood pressures mortality from stroke and ischaemic 
heart disease was almost twice(109). 
In 2003 combined effect of systolic, diastolicand mean blood pressure was studied 
on cardiovascular mortality by Pastor-Barriuso R etal concluded that the evidence 
for the lineaar association of systolic blood pressure with cardiovascular mortality 
is convincing, but a J-shaped association for diastolic blood pressure may develop 
at older age. The association of pulse pressure with coronary artery disease was bit 
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complex and non compelling hence use of it for prognostication was 
discouraged(110). 
A metaanalysis of cohort studies of baseline prehypertension and cardiovascular 
disease was studied by Shen L etal in 2013 which concluded that  prehypertension 
is associated with a significantly increased risk for development of coronary heart  
disease, particularly high-range prehypertension(111). 
In view of above mentioned data and enormous evidence of risk associated with 
hypertension; this can be further targeted for preventing risk of developing coronary 
artery disease. 
Smoking: In the study group of 106 population 42 (63.6%) patients in CAD group 
and  4 (10%) patients in control group were smokers which was highly significant 
(p<0.05; OR=15.7). This result is consistent with fact that smoking is an important 
risk factor for coronary artery disease. The pathophysiological mechanism can be 
explained as cigarette smoke consist of several toxic chemicals including nicotine, 
carbon monoxide, and other oxidant chemicals. Tobacco has been proved to cause 
endothelial dysfunction, inflammation, insulin resistance, alteration of lipid profile, 
hemodynamic alterations, and a hypercoagulable state. All of these act 
synergistically as pathobiologic mechanisms of atherothrombosis in tobacco 
users(112). 
In large multicentre CONFIRM study active smoking was found to be associated 
with 1.5 times higher risk of severe stenosis in 1 or 2 vessel disease and 2 fold 
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higher risk of severe stenosis in patients with 3 vessel disease compared to 
reformed smokers and non smokers (102). 
Another important study published in 2013 on the effect of quitting smoking in 
cardiovascular disease was conducted by Min etal demonstrated that the presence 
and severity of coronary blockages do not go away with quitting smoking, but that 
the risk of heart attack and death does(113). 
Dyslipidaemia: In the study population dyslipidaemia prevailed in 54.5 % of CAD 
group and 7.5 % in Non CAD group. Dyslpidaemia as well known risk factor for 
CAD was found to be significantly higher among cases (p<0.05 ; OR= 14.8). 
Dyslipidaemia has already been studied as one of the important modifiable risk 
factor in coronary artery disease in past. In 2004 Achari V et al conducted a study 
on Indian population to look for  association of modifiable risk factors in coronary 
artery disease. He concluded that among the  different risk factors assessed for 
CAD , dyslipidemia (especially altered TC/HDL ratio and increase LDL 
cholesterol), smoking habit, hypertension and diabetes mellitus were found to be 
associated with coronary artery disease in decreasing order of frequency. He also 
reported in premature CAD, dyslipidemia and (in males) smoking are of particular 
importance. These results are in accordance to our study which showed significant 
prevalence of all the above modifiable traditional risk factors in coronary artery 
disease group(114).  
Another interesting study published recently in 2014 by Namita Mahalle et al in 
2014 on Indian population to asses the pattern of dyslipidemia and its correlation 
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with cardiovascular risk factors in patients with proven coronary artery disease 
showed that Hypertriglyceridemia and low HDL cholesterol is common in patients 
with coronary artery disease compared with hypercholesterolemia. This suggests 
that need for different preventive strategy  required in Indian patients with coronary 
artery disease(115). 
In the present study lipid profile in  the CAD population was as : Total cholesterol 
163± 42 ; Triglycerides 150.5 ± 81.5 ; HDL 41.9 ± 12.8 ; LDL 101.8 ± 31.6 while 
in control group with no CAD the pattern of dyslipidaemia was as Total cholesterol 
155  ± 33.6; Triglycerides 134 ±  46.5; HDL 42.8 ±   10.8; LDL 95 ±  31.9. 
Although the mean values were relatively higher except HDL in CAD group but 
they were not statistically significant (p>0.05) which could easily be explained as 
most of the patients in study group were already on treatment for dyslipidaemia 
before entering the study. Also study population was also small in numbers. Hence 
considering the experience  from previous studies and present study dyslipidaemia 
can be targeted as one of the important modifiable risk factor in preventing 
coronary artery disease. 
Family history: In the study group of 106 patients 24 patient in CAD group and 1 
patient in Non CAD group gave history of CAD in family. The family history for 
coronary artery disease was considered to be positive if the subject gave  history of 
coronary artery disease in a parent or sibling before 60 years of age which could be 
of myocardial infarction, coronary artery bypass surgery, angina pectoris, or 
pathological exercise tolerance test diagnostic of ischemia. 
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In 1984 study by Shea S et al on CAD population to look for association of risk 
factors showed that family history stands out to be an important independent risk 
factor for coronary artery disease. His study results showed that comparison of 
patients at lowest risk (risk defined on the basis of American Heart Association risk 
model) with those at higher risk showed significantly greater cumulative frequency 
and earlier age of onset of all ischemic heart disease end points in population which 
had significant positive family history(116). 
Another international study by Friedlander Y et al in 1985 on assessing independent 
risk of positive family history of myocardial infarction in coronary artery disease 
concluded that  a  family history of heart attack was found to be statistically  
significant , indicating a relation with coronary heart disease that is independent of 
the other variables(117). 
In India; similar study done by Meenakshi Sharma et al in 2005 showed positive 
correlation of family history of myocardial infarction / CAD as an important 
independent risk factor in Indian population(118). 
So the results in our study are in accordance to both Indian and international studies 
where presence of positive family history have definite role in assessing risk of 
coronary artery disease. 
Family History: In the study group 25 patients among 40 patients in Non CAD 
group followed a physically active lifestyle while 23 patients among 66 patients in 
CAD group were physically active while rest 43 patients had sedentary lifestyle. 
The results in study was statistically insignificant (p=0.06). Its a well known fact 
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that an active lifestyle controls hypertension, obesity, dyslipidaemia, diabetes 
mellitus hence the risk of coronary artery disease. In our study population patients 
with active lifestyle were more protected from coronary artery disease although not 
statistically significant which can easily be explained with a small sample size of 
the study. 
Statement on Exercise in 1992 by AHA was among the first documents to conclude 
that physical inactivity is a major CAD risk factor(119). 
In 2003 an interesting study published by Paul d et al on defined the role of exercise 
and physical activity in prevention and treatment of atherosclerotic disease(120). 
Hence daily exercise and active life style should be instructed to our patients so as 
to prevent coronary artery disease. 
6.2 Risk factors found to be significant in both univariate and multivariate 
analyses: 
After logistic regression analysis the following risk factors were observed to have 
independent effects on coronary artery disease. 
Smoking is the most important and strongest risk factor associated with risk of 
coronary artery disease with OR 8.34 (2.14 – 32.50). Dyslipidaemia also stands out 
to be an important risk factor in both univariate and multivariate analysis with OR 
5.8 (1.35 – 25.12). Although age was not a statistically significant parameter in 
assessing risk in univariate model but after logistic regression (OR 1.06 (1.004  
1.13) ) this also stands out as an important risk for coronary artery disease. 
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Hence after reviewing results of univariate and multivariate regression analysis we 
can conclude that traditional modifiable risk factors play an important role in 
causation of coronary artery disease. .  Thus if we adequately address control of 
modifiable risk factors, we may delay onset of coronary artery disease in our 
susceptible population. 
6.3 Fasting Insulin and Insulin resistance analysis in the study group: 
In the study blood samples for estimation of fasting insulin and fasting blood sugar 
of 106 patients were taken prior to taking for coronary angiogram. The mean level 
of fasting serum insulin level in the CAD population was 9.73 ± 5.83 µU/ml and in 
control group was 5.62 ± 4.99 µU/ml which was found to be statistically significant 
between two groups (p<0.05) 
The mean level of fasting blood sugar in the CAD population was 99.20 ± 10.54 
mg/dl and the control group was 97.77 ± 11.21. Insulin resistance was estimated 
using both HOMA-IR and QUICKI indices. The mean HOMA-IR score in the CAD 
population was 2.41 ± 1.61 and the mean value of HOMA-IR in control group was 
1.32 ± 1.13. The p value for significance was 0.001; Odds ratio was 2.01 (95% CI 
1.35 – 3.01). 
The mean value of insulin resistance via QUICKI in CAD group was 0.349 ± 0.04 
and the control group the value was 0.395 ± 0.05. This value was also found to be 
significantly associated between two groups (p value < 0.005). 
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When all participants were analysed in scatter plot the correlation coefficient ‘R’ 
was 0.649 between QUICKI and Gensini scoring and 0.558 between HOMA-IR 
and gensini scoring. 
In the study group HOMA-IR in CAD population was further studied in presence of 
all the risk factors which are directly or indirectly associated with coronary artery 
disease. The results showed that in presence of other risk factors HOMAI-IR was 
not statistically significant although it increased the risk of CAD 1.2 times. This can 
easily be explained because insulin resistance signifies underlying metabolic 
syndrome and is not an isolated identity. So, risk factors like obesity, 
dyslipidaemia, hypertension, sedentary lifestyle, smoking, etc. leads to metabolic 
syndrome / insulin resistance syndrome and which is strongly associated with CAD. 
In our study population cases were further stratified into two groups with low 
HOMA-IR i.e with value <3 and population with high HOMA-IR i.e with value >3. 
The mean gensini score in group with low HOMA-IR score was 37 ± 28 and the 
mean value of gensini score in population with high HOMA-IR value was 83 ± 34. 
The association between two groups was found to be statistically significant 
(p<0.05). 
In the study 66 CAD cases were further stratified into 3 groups as described above. 
Out of these groups sensitivity and specificity of HOMA-IR and QUICKI in 
predicting Group C CAD i.e with gensini score ≥ 33 was studied using ROC plot. 
The results showed that HOMA-IR has sensitivity of 85 % and specificity of 66 % 
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for predicting group C CAD i.e with gensini score ≥ 33. QUICKI index showed 
sensitivity of 87 % and specificity of 67.5 % for prediction of the same. 
We also stratified our study (cases) population into 3 groups on the basis of gensini 
scoring (Group A GS 1-<14; B GS 14-32; C GS ≥ 33). Association of insulin 
resistance was than studien in 3 groups. The results showed that insulin resistance 
was significantly associated between group A and group C but neither between 
group A and B nor between group B and C. Insignificance of association of insulin 
resistance in group B compared to other two groups can be explained with less 
number of patients in B group. 
Although there is not much data in context to insulin resistance in non diabetic 
population but this factor has been grossly studied in diabetic population in 
numerous studies in past. 
In the large prospective study by Stephen et al in 1993 insulin resistance was shown 
to be an important predictor in development of diabetes(121). In 2014 study by 
Mahalle N et al  on association of dietary factors with insulin resistance and 
inflammatory markers in subjects with diabetes mellitus and coronary artery disease 
in Indian population showed strong correlation between dietary factors, insulin 
resistance (HOMA-IR) and inflammatory markers with coronary artery disease in 
diabetics(122). 
In an international study by Ntyintyane  LM et al in 2006 on Metabolic syndrome,  
and insulin resistance  prevalence  in urbanised South African blacks with coronary 
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artery disease showed that insulin resistance and metabolic syndrome were widely 
associated with coronary artery disease(123). 
Another interesting 10 years follow up study by Orchard TJ et al in 2003 conluded 
that greater glycemia does not seem to predict future CAD events rather insulin 
resistance predicts hard CAD end points in patients with type 1 diabetes mellitus. 
In 1998 Singh SB et al conducted study on zinc intake and risk of diabetes and 
coronary artery disease and factors associated with insulin resistance in rural and 
urban populations of North India showed that  lower consumption of dietary zinc 
and low serum zinc levels were associated with an increased prevalence of CAD 
and diabetes and several of their associated risk factors including hypertension, 
hypertriglyceridemia and other factors suggestive of insulin resistance in urban 
subjects(124). 
Some studies were also conducted in non diabetic patient groups to asses 
association of insulin resistance with coronary artery disease. In year 2000 Sheu 
WH et al conducted a study to predict coronary artery disease risk using insulin 
resistance, dyslipidaemia and hypertension. He concluded that patients without 
diabetes with coronary artery disease have abnormal glucose metabolism, 
hyperinsulinemia, and insulin resistance. Level of insulin resistance, plasma lipid 
values, and history of hypertension together accounted for one third of all risk for 
CAD, although degree of insulin resistance was the strongest risk factor(125). 
In 1996 Bressler P et al in 1996 conducted a study on insulin resistance in CAD 
population which concluded that subjects with angiographically documented CAD 
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are characterized by moderate-severe insulin resistance and hyperinsulinaemia and 
should be included in the metabolic and cardiovascular cluster of disorders that 
comprise the insulin resistance syndrome or "syndrome X(126)'. 
In 2007 study by Graner M et al on insulin resistance as predictor of angiographic 
severity of coronary artery disease showed that patients with more severe degree of 
insulin resistance have a more severe, extensive, and distal type of CAD than 
patients with lower degree of insulin resistance(127). 
To best of knowledge there is no Indian study on assessing insulin resistance as 
predictor of severity of coronary artery disease. Hence the present study was 
planned which showed that insulin resistance acts as an important predictor of 
coronary artery disease also correlating with severity of CAD. 
Thus insulin resistance which was supposed to be present only in diabetic 
individuals is also plays an important role in non diabetic CAD population. Hence 
keeping this concept in view all measures like exercise; weight loss; healthy diet,etc 
which helps in reducing/preventing insulin resistance should  be addressed in 
individuals who have CAD or are susceptible for CAD. 
 
6.4 Regional fat distribution via DEXA scan in the study group  
Regional fat analysis showed significantly low regional fat (Left arm; right arm; 
trunk; left leg and right leg; head; total fat) in CAD group but the percent fat trunk-
leg ratio and trunklimb ratio showed significantly higher values in CAD group. The 
VAT area in two study groups was insignificant (p>0.05). This can be explained by 
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the fact that mean BMI of the control group was 24.49 ± 3.22 which as per the 
Indian standards is overweight (> 23). Also this regional fat denotes subcutaneous 
fat which is less important compared to visceral fat.There is not much work done in 
context to regional fat distribution and severity of CAD but its association with 
cardiovascular risk factors has been reported in some studies. In 1997 association of 
regional fat distribution with cardiovascular rik factors was studied by Williams MJ 
et al. He concluded that intaabdominal and trunk fat were consistently positively 
related to CVD risk factors, whereas lower limb fat was consistently negatively 
related to cardiovascular risk, indicating that significant trunk-limb fat may be 
associated with higher risk  of cardiovascular disease(128).  
In 2010 Shay CM et al did work on diabetic population to look for the effect of 
regional body fat distribution on the risk of cardiovascular disease. He also reported 
that as the ratio of trunk/lower limb fat increases the risk of coronary artery disease 
also worsens(129).An important Indian study on association of visceral fat 
compared to subcutaneous fat with insulin resistance in non diabetics showed that 
Asian-Indian visceral fat but not subcutaneous fat was associated with higher 
insulin resistance and cardiovascular disease risk(130). 
Thus after reviewing the literature and previous work done on this topic as well as 
the results seen in our study we can conclude that its the visceral fat rather than 
subcutaneous abdominal fat and increasing trunk-lower limb fat ratio are more 
significantly associated with cardiovascular risk factors and future coronary artery 
disease risk. 
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7. Conclusion: 
The following conclusions can be derived from the present study: 
1. The well known traditional risk factors like age, male sex, smoking, obesity, etc 
were consistently associated with coronary artery disease. 
2. Smoking an important targetable risk factor was most strongly associated with 
coronary artery disease. 
3. Non-modifiable risk factors like a positive family history of CAD were  
important risk factors for development of coronary artery disease. Thus 
modifiable risk factors need to be addressed through various health programs to 
delay the development of coronary artery disease. 
4. Insulin resistance is an important contributor to metabolic syndrome which is 
closely associated with cardiovascular disease risk. Thus measures which help 
in reducing insulin resistance like weight loss and exercise should be thoroughly 
implemented in susceptible population group. 
5. Insulin resistance not only in diabetic individuals but also in non diabetics may play a 
crucial role in development of coronary artery disease.  However, since this is a cross 
sectional study, to say if this was a cause rather than an association is difficult to 
determine. 
6. Insulin resistance can be estimated easily by a computerised formula (HOMA-
IR & QUICKI) which can then be exploited in assessing cardiovascular disease 
risk or indirect prediction of severity of coronary artery disease. 
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7. Inta-abdominal subcutaneous fat association with risk of cardiovascular disease 
is a misconcept. Hence visceral fat should be given more importance in this 
context. 
8. Trunk-limb fat ratio using DEXA scan can also be used as a predictor for 
cardiovascular disease. 
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8. Recommendations: 
On the basis of study results we recommend: 
1. A Health promotion programme for susceptible CAD population which 
includes a comprehensive health package for assessment of metabolic 
syndrome, health educations, diet tips and an exercise programme 
2. Timed interval screening for insulin resistance in patients at risk of CAD 
so that adequate control measures can be reinforced. 
3. Active promotion of physical activity and exercises daily. 
4. Future studies should include larger sample size to study the phenomenon 
of insulin resistance and coronary heart disease. 
5. Consider clinical trials with therapeutic agents which target insulin 
resistance to reduce the progress of coronary heart disease. 
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                                                  ABBREVIATIONS 
BMI: Body Mass Index 
CAD: Coronary artery disease 
CASS: Coronary Artery Surgery Study 
CIMT: Carotid intima media thickness 
CVD: Cardiovascular disease 
CHD: Coronary heart disease 
DALYS: Disability adjusted life years 
DEXA: Dual energy X-ray absorptiometry 
ECG: Electrocardiogram 
GS: Gensini score 
HOMA-IR: Homeostatic Model assessment-Insulin resistance 
IR: Insulin Resistance 
HDL: High density Lipoprotein 
IHD: Ischemic heart disease 
LAD: Left anterior descending 
LCX: Left circumflex 
LDL: Low Density Lipoprotein 
IVUS: Intra vascular ultrasound 
QUICKI: Quantitative insulin check index 
RCA: Right coronary artery 
TG: Triglyceride 
TC: Total cholesterol 
 
 
 
 
                               ABBREVIATIONS FOR MASTER CHART 
I.D.-Hospital identification number 
S- Sex 1- Male, 2- Female 
Ht- Height 
Wt- Weight 
BMI- Body mass index 
Sm- Smoker 1- YES, 2- NO 
H- Hypertension 1-YES, 2- NO 
Ob- Obesity 1- YES, 2- NO 
P.A- Physically active 1- YES, 2- NO 
DY- Dyslipidemia 1- YES, 2- NO 
F.H- Family history 1- YES, 2- NO 
CKD: Chronic kidney disease 1- YES, 2- NO 
PAD- Peripheral artery disease 1- YES, 2- NO 
CVA- Cerebrovascular accident 1- YES, 2- NO 
IHD- History or treatment of IHD 1- YES, 2- NO 
TC- Total cholesterol, TG- Triglyceride, HDL-High density Lipoprotein, LDL-Low density 
lipoprotein 
PR- Pulse rate 
Hb- Haemoglobin 
Ct- Creatinine 
AC- Antecebum blood sugar 
PC- Postcebum blood sugar 
In- Fasting serum insulin levels 
HbA1c: Glycosylated haemoglobin 
HOMA-IR- Homeostatic Model assessment-Insulin resistance 
QUICKI- Quantitative insulin check index 
GS- Gensini score 
                                                 PATIENT INFORMATION SHEET 
Department of Cardiology;Christian Medical College, Vellore 
 “Insulin resistance and its correlation with severity of Coronary Artery Disease in patients 
without     diabetes” 
You are being requested to participate in this study which will enroll consecutive non diabetic 
patients in general and private wards of Department of Cardiology, CMC who are posted for 
Coronary Angiogram. All the patients will be treated as per standard guidelines of ischemic heart 
disease. All routine blood test, cardiogram (ECG), chest x-ray & scanning of heart to check 
pumping (ECHO) will be done prior to the Coronary Angiogram. The procedure will be done as 
per routine protocols with 4 hours fasting prior to the procedure. Access will  be through your 
Right hand most of the times and if not possible then through Right groin. A thin wire will be 
passed through your access site and < 10-15 ml dye will be used to asses the condition of your 
arteries in heart. Coronary Angiogram do have the risk of haematoma (0.43%), allergic contrast 
reaction including Contrast induced Nephropathy(0.37%), CVA(0.07%) . However accepting for 
present study does not add up any risk.  
If you take part what will you have to do? 
If you agree to participate in this study, we will do one special blood test on the day of 
procedure. Blood samples (5 ml) for measurement of HbA1C/ Insulin assay will be collected 
on the morning of angiogram. All the treatments/procedures will be continued and your 
regular treatment will not be changed during this study. You will be observed in the ward till 
the time of discharge. We will also perform a DEXA Scan (Dual energy X-RAY 
Absorptiometry) free of cost to estimate your body fat composition. No complications are 
expected with the DEXA procedure, as the dosage of radiation exposure is minimal. 
Pregnant women are excluded from the study to reduce the radiation exposure. 
What researchers will learn from the study? 
This research is being done to look for insulin resistance in patients without diabetes and to 
correlate it with severity of coronary artery disease via standard score (Gensini Score). We 
will also look for body fat composition via DEXA and correlate with CAD severity. This 
research will help us predict that patients who do not have frank diabetes and have CAD also 
have underlying insulin resistance as a predisposing factor for CAD. 
Can you withdraw from this study after it starts? 
Your participation in this study is entirely voluntary and you are also free to decide to 
withdraw permission to participate in this study. If you do so, this will not affect your usual 
treatment at this hospital in any way.  
Will you have to pay for the blood test?  
The special blood test will be totally free to you and you will not be charged anything extra 
for this special test.  
Will your personal details be kept confidential? 
Yes. The results of this study will be published in a medical journal but you will not be 
identified by name in any publication or presentation of results. 
Is there any risk associated with this study? 
No. There is no harm or any risk to you from the study, as no new therapy or procedure is 
planned on study participants during the study period. 
If you have any further questions, please ask  Dr.Geetesh Manik  or duty doctor at  
J ward/CCU/CPU (Tel: 0416 2282631/ 2283122/ 2282646) or Email: 
cardio2@cmcvellore.ac.in 
                                            PATIENT CONSENT FORM 
Study Title: “Insulin resistance and its correlation with severity of Coronary Artery 
Disease in patients without diabetes ” 
Participant’s Name: 
Date of Birth / Age (years): 
 (i) I confirm that I have read and understood the information sheet dated _________ for the 
above study and have had the opportunity to ask questions. [ ] 
(ii) I understand that my participation in the study is voluntary and that I am free to withdraw 
at any time, without giving any reason, without my medical care or legal rights being 
affected. [ ] 
(iii) I understand that the Ethics Committee and the regulatory authorities will not need my 
permission to look at my health records both in respect of the current study and any further 
research that may be conducted in relation to it, even if I withdraw from the trial. I agree to 
this access. However, I understand that my identity will not be revealed in any information 
released to third parties or published. [ ] 
(iv) I agree not to restrict the use of any data or results that arise from this study provided 
such a use is only for scientific purpose(s). [ ] 
(v) I agree to take part in the above study. [ ] 
Signature of the Subject/Legally Acceptable Representative: ____________________ 
Date: _____/_____/______ 
Signatory’s Name: _________________________________ 
Signature of the Principal Investigator: ________________________ 
Date: _____/_____/______ 
Principal Investigator’s Name: _________________________ 
Signature of the Witness: ___________________________ 
Date: _____/_____/_______  
Name of the Witness: ______________________________ (Relation to participant) 
 
(Or Thumb impression) 
                                                                     Proforma 
Date:                                                                                                                          
Ward: 
Patients Name:                                                          Hospital  Id: 
 
Address & Contact no.:              
Age:                        Sex:                     Ht. :                  Wt.:               BMI: 
 
Risk Factors:(Y/N) with duration 
1. Smoker (current or past) 
2. Hypertension 
3. Obesity (as per BMI) 
4. Physicaly active: 
5. Dyslipidaemia 
6. Family h/o 
7. CKD 
8. PAD 
9. CVA 
10. IHD 
 
Presenting Complaints: 
 
Clinical Examination: 
P        I     C     C       L      E 
P =                                                         BP = 
R/S=       CVS= 
 
 
 
Investigations: 
1. ECG: 
2. ECHO: 
3. Chest XRAY: 
4. Blood Investigations: 
Hb: 
Urea: 
Creatinine: 
Lipid profile:  TC=                           TG=                          HDL=                          LDL= 
AC=                                                 PC=                                                      Hba1c= 
Fasting Serum Insulin= 
HOMA IR:   fasting Glucose(mg/dl) x fasting Insulin(µU/mL) / 405  = 
QUICKI:     1 / (log(fasting insulin µU/mL) + log(fasting glucose mg/dL)) = 
CAG: 
1. Date: 
2. Findings: (Site/Severity/Number of lesions) 
3. Gensini Score: 
4. Dexa Scan: 
REGION                                                             % FAT 
LT Arm 
Rt Arm 
Trunk 
Lt Leg 
Rt leg 
Head 
Total                                               
 
                                                      SIGNATURE OF INVESTIGATOR 
                                                                           Dr. Geetesh Manik 
 
Sn Name H.No. age S Ht Wt BMI B Gr Sm H ob PA DL FH CKD PAD CVA IHD PR BPS BPD Hb Ct TC TG HDL LDL AC PC H1C In GS Ltaf rtaf Trf Ltlf Rtlf Hf Ti f %ftlr Vat Hir Log i LogAC Qi
1 Sreedevi                463308f 43 F 1.6 72 28 Gr3 N N 1 N N N N N N N 74 130 80 13 0.71 193 207 30 134 105 101 6 3.39 0 42.7 42.8 39.5 43.4 43.5 23.4 40.4 0.91 88 0.88 0.53 2.02 0.39
2 Anjan Das               645387f 59 M 1.7 70 24 Gr2 N N 2 Y N N N N N N 78 136 82 14 1.4 135 98 56 61 101 143 6 6.93 0 19.6 18.8 23.5 16.8 18.5 20.3 20.8 1.33 110 1.73 0.84 2 0.35
3 Bablu Roy               663416c 59 M 1.6 70 28 Gr3 Y N 1 N Y Y N N N Y 74 130 80 15 1.1 96 136 37 37 92 128 6 5.89 0 23.8 24.2 32.7 24.9 27.5 20.1 28.9 1.25 149 1.34 0.77 1.96 0.37
4 Baby Chaterjee          680999f 51 F 1.5 56 26 Gr3 N Y 1 Y N N N N N N 80 140 90 13 1.1 228 179 54 164 105 126 6 6.21 0 42 43.4 32.6 37.5 38.4 21.2 34.5 0.86 113 1.61 0.79 2.02 0.36
5 Bansiballa Sen          715164f 62 M 1.6 54 22 Gr2 N N 2 N Y N N N N N 76 120 70 13 0.94 173 174 35 112 103 97 6 6.8 0 24 25.4 24.8 26 25.8 19.6 24.8 0.96 104 1.73 0.83 2.01 0.35
6 BHajahari               715687f 59 M 1.7 65 23 Gr2 N N 2 Y N N N N N N 70 110 80 12 0.99 152 96 41 106 93 86 6 3.55 0 23 21.2 26.1 22.4 23.2 20.4 24.1 1.15 128 0.82 0.55 1.97 0.4
7 Chaitali                715618f 52 F 1.6 59 23 Gr2 N Y 2 N N N N N N N 63 130 80 11 0.99 149 85 54 80 101 118 6 10.8 0 48.7 47.3 45.3 44.1 44.3 220 43.7 1.02 152 2.69 1.03 2 0.33
8 Gauri Seal              684440c 52 F 1.5 59 25 Gr3 N N 1 N N N N N N N 77 115 72 10 0.77 172 140 51 102 100 98 6 9.5 0 35.8 34.3 37 42.8 42.8 20.9 37.6 0.86 107 2.35 0.98 2 0.34
9 Gayatri devi            489456d 58 F 1.5 64 28 Gr3 Y N 1 N N N N N N N 74 150 80 13 0.95 224 116 55 140 101 122 5 7.46 0 39.1 39.4 33.1 38.6 36.7 20 34.3 0.88 79 1.86 0.87 2 0.35
10 Govinda Reddy           708299f 68 M 1.7 56 20 Gr2 N N 2 N N N N N N N 102 129 74 12 0.94 120 62 46 64 97 126 6 8.54 0 22 19 20.9 34.4 33.9 19.1 25.3 0.61 62 2.05 0.93 1.99 0.34
11 Kamal Kumar             420133f 53 M 1.6 65 25 Gr2 N Y 2 Y N N N N N N 80 150 80 15 1.3 149 85 36 85 89 94 6 8.7 0 22.2 20.6 23 19.1 19.1 20.4 21.4 1.2 134 1.91 0.94 1.95 0.35
12 Khokhan Ghosh           718159f 43 M 1.7 60 22 Gr2 N N 2 Y N N N N N N 64 120 80 14 1 196 202 42 146 97 95 5 4.34 0 21 23 2.4 25.3 21.3 23.9 22.8 0.96 71 1.04 0.64 1.99 0.38
13 Lali Devi               694754f 56 F 1.5 60 27 Gr3 N N 1 N N N N N N N 70 130 80 11 0.95 182 77 36 127 84 101 6 1.73 0 46.3 43.5 33.1 45.2 45 20.4 37.9 0.73 162 0.36 0.24 1.92 0.46
14 Madan Mohan             729084f 57 M 1.6 65 25 Gr2 N Y 2 Y N N N N N N 74 110 80 14 0.97 103 79 41 49 93 97 5 4.18 0 24.6 23.9 28.4 28.9 25.5 24 27.2 1.04 127 0.96 0.62 1.97 0.39
15 Palani Samy             686540f 50 M 1.7 100 36 Gr 5 N Y 1 N N N N N N N 56 134 80 14 1.1 195 121 41 137 85 110 6 17.4 0 44.1 41.8 38.5 35.9 37.8 20.5 37.5 1.04 196 3.65 1.24 1.93 0.32
16 Parvathi Devi           725878f 39 F 1.5 69 29 Gr3 N N 1 Y N N N N N N 70 110 70 12 0.44 168 97 42 111 84 99 5 7.35 0 44.6 42.4 36.7 37.4 37.7 24.7 36.8 0.98 103 1.52 0.87 1.92 0.36
17 Rekha Roy               702230f 44 F 1.4 50 26 Gr3 N N 1 N Y N N N N N 72 136 78 12 0.89 198 122 47 128 95 96 5 5.3 0 38.7 37.9 39.6 36.1 36.3 19.8 36.9 1.09 129 1.24 0.72 1.98 0.37
18 Sagunthi.R              694055F 42 F 1.6 57 23 Gr2 N Y 2 N N N N N N N 69 114 76 12 0.97 101 79 37 54 95 121 5 19.4 0 44.4 42.7 32.1 40.8 43.2 19.7 36.1 0.76 79 4.55 1.29 1.98 0.31
19 Samir Chakraborty       660999f 54 M 1.7 69 24 Gr2 Y Y 2 Y N N N N N N 57 160 76 14 1.1 143 141 29 88 98 110 6 8.98 0 26.5 25.6 27 24.1 23.8 19.9 25.4 1.13 138 2.17 0.95 1.99 0.34
20 Savitri                 713482d 49 F 1.6 75 30 Gr4 Y N 1 Y N N N N N N 83 133 82 13 0.7 177 82 45 119 93 105 6 22.1 0 40.9 42.5 36.8 40.8 43.8 20 38.3 0.87 140 5.07 1.34 1.97 0.3
21 Subrata Nag             723955f 54 M 1.6 58 22 Gr2 N N 2 Y N N N N N N 74 130 80 13 1.4 95 170 25 49 81 119 6 7.39 0 24.6 26.3 29.7 27.2 26.6 20.4 27.7 1.11 162 1.48 0.87 1.91 0.36
22 Sujatadevi              719602f 49 F 1.5 47 22 Gr2 N N 2 N N N N N N N 74 130 80 12 0.84 155 241 46 70 76 100 6 9.24 0 41.6 42.5 33.6 35.5 36.2 19.3 34.1 0.94 104 1.73 0.97 1.88 0.35
23 Sujit Deb               700812f 55 M 1.7 85 29 Gr3 N Y 1 Y N N N N N N 70 126 81 13 1.4 155 143 36 98 105 109 6 2.5 0 20.6 19 24.8 18.6 19.3 20.4 22 1.31 136 0.65 0.4 2.02 0.41
24 Susanta Saha            705189f 55 M 1.7 57 20 Gr2 N N 2 N N N N N N N 80 130 80 14 1.1 196 91 59 122 85 118 5 1.9 0 19.3 20.9 18.4 19.2 20.6 20.1 19.3 0.92 96 0.4 0.28 1.93 0.45
25 Thanigai Vasan S        709057F 64 M 1.6 64 26 Gr3 N Y 1 Y N N N N N N 72 120 80 13 1 162 93 44 102 106 98 5 5 0 29.4 29.9 28 26.7 25.8 20 27.1 1.07 142 1.31 0.7 2.03 0.37
26 Uttam                   706008f 37 M 1.7 55 20 Gr2 N N 2 Y N N N N N N 88 141 74 15 0.9 142 139 40 79 117 99 6 4.8 0 27.1 28.6 31.9 29 31.1 20.7 29.9 1.06 114 1.39 0.68 2.07 0.36
27 Tapan Kumar Biswas      949110d 50 M 1.6 58 23 Gr2 N N 2 N N N N N N N 84 130 80 14 1 114 143 31 62 100 102 5 5.7 0 22.8 28.5 33.6 28.3 25.8 24 30 1.24 155 1.41 0.76 2 0.36
28 Tapati Singha           745695f 48 F 1.6 58 23 Gr2 N N 2 Y N N N N N N 84 110 70 12 0.58 185 122 40 123 111 90 5 3.46 0 40.9 35.9 31.7 42.9 41.4 23.4 35.8 0.75 75 0.95 0.54 2.05 0.39
29 Dilip kumar das         744743f 60 M 1.6 57 22 Gr2 N N 2 Y N N N N N N 84 110 70 13 0.91 169 113 65 89 119 139 5 1.35 0 29.2 23.4 32.1 28.6 28.2 23.8 29.6 1.13 113 0.4 0.13 2.08 0.45
30 Kunwati                 747457f 48 F 1.6 64 26 Gr3 N N 1 Y N N N N N N 69 110 70 11 0.57 121 217 43 52 101 88 5 1.2 0 35.3 33.5 32.5 29.5 29.2 19.3 30.8 1.11 114 0.3 0.08 2 0.48
31 Gobinda kumar saha      747651f 49 M 1.7 70 24 Gr2 N N 2 N N N N N N N 78 120 80 13 0.73 185 224 37 120 100 122 5 1.3 0 35.9 37.2 34.4 35.3 32.3 23.8 33.8 1.02 179 0.32 0.11 2 0.47
32 Chandra Devi            722577F 66 F 1.5 51 24 Gr2 N N 2 Y N N N N N N 84 106 60 13 0.75 142 90 76 53 92 130 6 1.2 0 42.4 40.4 37.8 45.3 44.7 19.9 39.2 0.84 123 0.27 0.08 1.96 0.49
33 Inbanala                617396f 55 F 1.5 55 23 Gr2 N N 2 Y N N N N N N 84 120 70 12 0.75 156 199 27 96 110 93 6 1.63 0 39.8 39.2 29.6 38.3 39.2 34.4 20.1 0.76 92 0.44 0.21 2.04 0.44
34 Jharani Bai             408975b 39 F 1.6 54 22 Gr2 N N 2 Y N N N N N N 68 100 60 8 0.63 116 94 46 78 93 92 5 1.3 0 38.6 35.4 32.8 35 34.8 20.1 33.2 0.94 97 0.3 0.11 1.97 0.48
35 Ashish Jana             762868F 45 M 1.7 60 21 Gr2 N N 2 Y N N N N N N 60 106 70 12 0.9 150 185 43 79 135 108 6 1.4 0 24.5 25.4 28.5 25.3 24.1 19.6 26.2 1.16 110 0.47 0.15 2.13 0.44
36 Sikha Das               761779f 48 F 1.6 54 22 Gr2 N N 2 Y N N N N N N 68 110 70 12 0.75 140 150 58 127 96 97 6 1.4 0 48.9 49.4 41.4 41.5 42.6 20.6 41.2 0.99 123 0.33 0.15 1.98 0.47
37 Usha Lama               765372f 63 F 1.6 60 25 Gr2 N N 2 Y N N N N N N 70 110 70 8.5 1 133 146 43 68 93 108 5 1.2 0 47.9 47.8 41.9 43 43.3 21 41.5 0.97 177 0.28 0.08 1.97 0.49
38 Amar Chodhuray          624209b 55 M 1.7 64 23 Gr2 N N 2 Y N N N N N N 88 100 70 13 1.2 142 159 41 86 104 99 5 1.5 0 27.7 26.1 27.9 28.1 27 23.5 27.3 1.01 82 0.39 0.18 2.02 0.46
39 Senthil Kumar           765762f 53 M 1.7 72 25 Gr3 N N 1 Y N N N N N N 80 110 60 14 0.93 170 116 32 132 81 103 6 1.1 0 32.6 29.9 28 29.8 30 19.5 28.6 0.94 137 0.22 0.04 1.91 0.51
40 Binod Roy               446659f 35 M 1.7 60 22 Gr2 N N 2 Y N N N N N N 80 100 60 12 0.83 118 150 25 74 95 111 5 1.9 0 22 20.4 19.2 26.1 25.3 19.8 21.8 0.75 107 0.45 0.28 1.98 0.44
41 Bala Krishan            713580f 74 M 1.6 51 20 Gr2 N Y 2 Y N N N N N N 74 140 80 12 1.1 206 101 49 137 101 101 6 4.09 3 15.7 20.5 24.5 18 17.7 19.5 21.4 1.37 107 1.02 0.61 2 0.38
42 Girish Das              301771d 55 M 1.6 69 27 Gr3 Y Y 1 Y Y N N N N Y 62 132 72 13 1.2 164 203 33 110 98 100 6 13.5 11 24.3 23.8 27.6 25.7 26.6 20 26.3 1.06 131 3.27 1.13 1.99 0.32
43 Jamuna Devi             708459f 48 F 1.6 60 24 Gr2 N Y 2 N N N N N N N 72 140 90 11 1.4 171 155 47 99 103 140 6 6.82 14 52.4 51.4 42.4 44.4 46.8 22.7 43.3 0.93 145 1.73 0.83 2.01 0.35
44 Laxman                  666020f 48 M 1.6 68 28 Gr3 N N 1 Y N N N N N N 78 136 80 12 1.4 131 116 52 68 89 100 5 3.2 3 21.3 22 24.8 20 20.4 19.9 22.6 1.22 84 0.7 0.51 1.95 0.41
45 Mary Stella             701921f 72 F 1.6 62 25 Gr2 N Y 2 Y Y N N N N N 72 147 94 12 0.64 239 93 52 165 115 99 6 4.18 10 37.9 43.8 39.7 47.4 46 20.3 40.8 0.85 168 1.19 0.62 2.06 0.37
46 Nirmalinda              361143f 58 M 1.7 55 20 Gr2 Y N 2 N Y N N N N N 78 130 80 13 1.4 116 76 44 60 90 122 6 7.27 14 26.4 27.8 26.9 27.2 27.4 23.3 26.7 0.98 81 1.62 0.86 1.95 0.36
47 Sudhir Chandra          707991f 51 M 1.6 55 20 Gr2 Y N 2 Y N N N N N Y 57 133 93 16 1.2 195 314 29 115 87 113 6 4.02 7 17.7 18.2 21.4 17 19 20 19.8 1.19 108 0.86 0.6 1.94 0.39
48 Sutapa                  043147f 48 F 1.5 70 31 Gr4 Y N 1 N Y N N N N N 74 130 80 13 0.99 207 122 67 129 85 111 5 5.72 2 34.5 36.8 33.8 36.1 39 19.8 34.4 0.9 109 1.2 0.76 1.93 0.37
49 Shivani Mukherjee       744795f 48 F 1.5 54 25 Gr3 N N 1 Y N N N N N N 74 120 80 13 0.9 111 124 48 78 80 100 6 2.63 1 42.5 37.7 38.4 38.7 38.5 23.5 37.6 1 107 0.52 0.42 1.9 0.43
50 Sudhani Dulal           183456f 76 M 1.6 62 24 Gr2 N N 2 Y N N N N N N 78 140 70 12 1.1 82 100 42 44 97 114 6 1.23 2 24.3 21.2 24.4 24.5 26.7 23.7 24.5 0.95 111 0.29 0.09 1.99 0.48
51 Padama Dutta            728293f 58 F 1.5 54 23 Gr2 N N 2 Y N N N N N N 64 110 68 11 0.67 155 109 43 95 123 105 5 1.45 2 46 50.9 46.8 45.8 48.5 24.1 45.9 0.99 154 0.44 0.16 2.09 0.44
52 Kamal Kanti Dey         747363f 56 M 1.8 61 20 Gr2 N N 2 Y N N N N N N 68 130 70 13 0.92 99 145 34 49 93 92 5 1.69 5 13 12 14.5 17.1 17.5 19.6 15.4 0.84 63 0.39 0.23 1.97 0.46
53 Sandhan das             603091f 56 M 1.7 63 23 Gr2 Y N 2 Y N N N N N N 70 130 80 13 0.79 252 337 33 170 94 118 6 3.4 12 21.8 21.9 27.3 28 26.9 23.3 26.6 0.99 107 0.79 0.53 1.97 0.4
54 Biswanath Ghosh         723205f 51 M 1.6 61 23 Gr2 N N 2 Y Y N N N N N 84 110 70 15 1.1 260 273 65 160 110 100 5 1.87 4 20.1 20.7 26.1 19.8 21.1 20.3 23.2 1.28 120 0.51 0.27 2.04 0.43
Sn Name H.No. age S Ht Wt BMI B Gr Sm H Ob PA DL FH CKD PKD CVA IHD PR BPS BPD Hb Ct TC TG HDL LDL AC PC H1C In GS Ltaf rtaf Trf Ltlf Rtlf Hf Ti f %ftlr Vat Hir Log i LogAC Qi
55 Bibhaman Roy            707851F 50 M 1.7 70 25 Gr3 Y N 1 Y Y N N N N N 72 130 80 14 1.3 100 108 30 55 112 115 5 5.2 26.5 35.8 32.3 32.2 28.5 27.7 23.9 30.4 1.15 124 1.44 0.72 2.05 0.36
56 Mrinal Kanti Sen        647871f 73 M 1.6 73 27 Gr3 Y Y 1 Y Y N N N N N 80 144 86 14 0.75 221 182 40 151 86 100 6 6.8 26 25.9 27.4 29 22.3 25.1 19.6 26.4 1.22 151 1.44 0.83 1.93 0.36
57 Sitaram                 297608f 68 M 1.7 68 24 Gr2 N Y 2 N N N N N N N 64 130 80 13 1.3 116 104 44 54 91 95 6 7.26 22 31.1 26.4 28 29 29.4 24.4 28.2 0.96 110 1.63 0.86 1.96 0.35
58 Subodh Kumar            302680d 45 M 1.6 50 21 Gr2 N N 2 N N N N N N Y 77 110 69 14 1.3 124 87 44 75 96 95 6 4.7 28 21 22.2 22.3 23.7 24.6 20 22.6 0.92 77 1.11 0.67 1.98 0.38
59 Suvir kumar             690362f 53 M 1.7 78 26 Gr3 Y Y 1 N N Y N N N N 74 140 80 15 1.2 155 171 36 95 111 130 6 9.26 15 24 24.1 29.7 24.6 25.8 9.9 26.9 1.18 156 2.54 0.97 2.05 0.33
60 Sripat Charan           878534d 58 M 1.7 78 27 Gr3 Y Y 1 N Y Y N N N N 78 138 100 14 1.1 163 168 37 102 94 113 6 9.9 30 24.7 23 23.7 25 25.2 20.2 23.9 0.95 82 2.3 1 1.97 0.34
61 Ajay ahmed khan         722630f 58 M 1.6 70 26 Gr3 N N 1 Y N N N N N N 80 110 70 14 0.99 112 229 30 53 105 137 6 18.9 112 23 22.3 20.5 19.4 19.2 20.6 20.3 1.06 139 4.89 1.28 2.02 0.3
62 Amiya Mondal            719006f 49 M 1.7 60 21 Gr2 Y Y 2 N Y N N N N N 70 130 90 14 1.2 147 95 39 96 89 139 6 12.5 114 15.4 16.2 22.9 17.2 18.2 20.2 20.3 1.29 101 2.75 1.1 1.95 0.33
63 Asim Akash              614454f 57 M 1.8 84 26 Gr3 N N 1 Y N N N N N N 68 130 80 13 1.4 167 111 34 113 99 136 6 7.7 44 26.1 28 29.6 27.9 28.4 19.6 28.3 1.05 146 1.88 0.89 2 0.35
64 BelaBharath             479854f 64 F 1.6 41 17 Gr1 N N 2 Y N N N N N N 74 135 76 12 0.71 266 105 60 187 101 106 6 4.5 56.5 22.2 22.6 30.2 27.3 26.3 20.4 27.4 1.13 64 1.12 0.65 2 0.38
65 Bikash Mondal           996656d 37 M 1.6 54 22 Gr2 Y N 2 Y Y N N N N N 78 124 80 14 1.1 185 89 82 130 106 98 5 7.1 41 23.8 26.3 27.6 25.8 27.2 20.2 26.4 1.04 110 1.86 0.85 2.03 0.35
66 Bipan Kumar             699821f 56 M 1.6 62 25 Gr2 N Y 2 N N N N N N N 78 130 80 15 0.93 189 201 34 118 92 98 5 9.9 47 28.5 36.2 31.6 29.7 30.2 23.8 30.7 1.05 162 2.25 1 1.96 0.34
67 Biswanath Gorai         629481d 62 M 1.6 64 26 Gr3 N Y 1 Y N N N N N N 74 110 80 14 0.87 128 93 60 57 95 138 6 2.51 55 25.1 25.4 28.2 33.1 27.5 24 28.2 0.93 120 0.59 0.4 1.98 0.42
68 Chita Majumdar          723415f 50 F 1.6 58 24 Gr2 N N 2 N N N N N N N 70 120 80 13 0.59 119 148 46 61 104 174 5 2.37 59.5 47.4 45.1 42 42.8 43.1 24.3 41.7 0.98 134 0.61 0.37 2.02 0.42
69 Gangaram                9697341 48 M 1.6 72 28 Gr3 Y N 1 Y N N N N N N 84 120 80 13 1 113 90 39 56 85 94 6 8.43 38 17.4 16.8 19.1 16.5 17.4 19.9 18.3 1.12 104 1.77 0.93 1.93 0.35
70 Girdharlal              002822d 58 M 1.7 77 27 Gr3 Y N 1 N N N N N N N 70 120 70 13 1.2 113 79 36 59 96 91 6 12.9 41 25.1 26.4 23.2 26.2 28.5 20.3 24.7 0.85 122 3.06 1.11 1.98 0.32
71 Hamid Hussain           709417f 32 M 1.7 78 28 Gr3 Y N 1 Y N N N N N N 78 121 73 13 0.99 75 67 22 41 98 113 5 12.8 106 23.4 22.7 23.7 22 23.4 20.3 23.1 1.05 101 3.1 1.11 1.99 0.32
72 Karunakaran             802163d 66 M 1.5 55 23 Gr2 N Y 2 N N N N N N N 78 130 80 14 0.79 247 222 33 181 96 126 6 4.87 51.5 30.8 31.2 28.5 30.6 27.1 23.4 28.5 0.99 110 1.15 0.69 1.98 0.37
73 Kishore Pal             717438f 40 M 1.7 70 25 Gr3 Y Y 2 Y N N N N N N 90 160 100 15 1.4 184 130 44 116 80 119 6 10.1 40 17.1 20 3 8.3 20.8 20.3 21.2 1.18 103 2 1 1.9 0.34
74 Mohd Harim Rashid       719293f 54 M 1.6 73 27 Gr3 Y Y 1 N N N N N N N 74 120 70 14 1.4 124 118 29 89 91 112 6 18 98 24.1 22.7 26.9 23.9 26.5 20.7 25.5 1.07 136 4.04 1.26 1.96 0.31
75 Nityanarayan            450082f 59 M 1.7 70 25 Gr2 Y Y 2 N N N N N N N 70 150 70 13 1.2 150 121 40 87 90 106 6 13.9 42.5 20.4 18.9 21.5 17.3 18.5 20.5 20 1.2 119 3.09 1.14 1.95 0.32
76 Purshottam              707025d 59 M 1.6 77 29 Gr3 N N 1 N Y N N N N N 80 140 80 14 1.1 169 227 33 101 99 135 6 12.3 112.5 35.3 31.3 32.2 28.2 29.5 20.6 30.5 1.11 163 3.01 1.09 2 0.32
77 Samir Kumar             746056c 44 M 1.6 60 23 Gr2 Y Y 2 Y N N Y N N N 73 130 87 14 1.2 98 105 36 45 93 107 6 22.1 49 21.5 24.9 28.5 20.7 23.8 20.3 25.4 1.29 126 5.07 1.34 1.97 0.3
78 Sanath Kumar            710099f 51 M 1.6 54 20 Gr2 Y N 2 Y Y N N N N N 69 128 77 14 1.2 201 139 45 142 107 108 6 10.6 94 21.1 22.2 22.2 19.5 20.1 19.3 21.2 1.12 92 2.8 1.03 2.03 0.33
79 Santosh Das             648160f 72 M 1.6 58 23 Gr2 N N 2 N N N N N N N 74 110 80 13 1.2 265 74 84 170 109 103 6 11.4 98 23.1 22.8 17.4 26.5 25.2 23.2 21.5 0.68 47 3.07 1.06 2.04 0.32
80 Sridhar Roy             213947c 58 M 1.6 48 19 Gr2 Y Y 2 N N N N N N N 74 130 80 11 0.97 91 115 29 138 104 105 5 5.32 38 24.9 23.1 24.7 26.4 26.5 20.2 24.9 0.94 99 1.37 0.73 2.02 0.36
81 Sumit Bhattacharjee     702079f 62 M 1.5 54 24 Gr2 N N 2 N N N N N N Y 78 112 74 11 1.1 123 152 47 52 128 148 6 31.4 39 17.8 21.2 20.8 18.8 18.2 19.8 19.9 1.12 92 9.92 1.5 2.11 0.28
82 Sunil Kumar             425895f 61 M 1.6 49 18 Gr1 N N 2 N N N N N N N 88 130 80 13 1.2 134 71 63 68 96 142 6 13.8 59.5 24.3 23.4 18.8 23.3 24.9 19.3 21.3 0.78 74 3.27 1.14 1.98 0.32
83 Shantipada Nath         477484f 49 M 1.5 78 33 Gr4 Y Y 1 N Y Y N Y Y N 74 138 80 14 0.79 239 238 28 174 109 117 6 8.2 76 30.5 28.6 32.9 31 29.5 24.3 31.1 1.09 129 2.21 0.91 2.04 0.34
84 Amya Baurai             744194f 62 M 1.6 71 27 Gr3 Y Y 1 N Y Y N Y Y N 78 148 90 12 0.98 230 70 80 137 108 113 5 9.94 48 30.8 32.4 29.5 30.9 29.5 24.8 29.7 0.98 130 2.65 1 2.03 0.33
85 Jyoti Prakash           723104f 62 M 1.6 78 29 Gr3 Y Y 1 N Y Y N N N N 78 158 90 12 0.84 177 331 33 98 106 114 6 7.55 40 28.7 27.8 28.7 30.3 27.5 24.1 28.4 0.99 146 1.98 0.88 2.03 0.34
86 Dhanashekar             744309f 55 M 1.6 79 30 Gr3 Y Y 1 N Y Y N N N N 80 148 100 13 1.1 144 84 49 89 109 139 6 11.6 94 19.3 20.1 21.4 21.2 21 19.9 21 1.01 72 3.12 1.06 2.04 0.32
87 Kripanath das           747901f 57 M 1.6 73 28 Gr3 Y Y 1 N Y Y N N N N 87 158 100 12 0.86 125 86 35 74 98 158 6 17.6 93 24.7 24.4 29.6 24.5 25.9 24 27.1 1.17 122 4.26 1.25 1.99 0.31
88 Santosh Devi Agrawal    728287f 56 F 1.5 68 29 Gr3 N Y 1 N Y N N N N N 78 148 98 12 0.73 138 124 36 83 120 123 6 16.5 51 48 48 39.5 45.9 45.7 23.7 41.4 0.86 142 4.89 1.22 2.08 0.3
89 Tulsi Thakur            743569f 55 F 1.6 68 26 Gr3 N Y 1 N Y Y N N N N 84 150 106 13 0.96 225 131 35 166 97 114 6 14.9 68 24.7 27.6 28.8 23.8 23.8 20.1 26.4 1.21 135 3.57 1.17 1.99 0.32
90 Murari Lal Singh        386315f 59 M 1.6 64 25 Gr2 Y N 2 N Y N N N N N 88 140 70 13 0.78 207 157 37 145 97 103 5 6.95 39 28.1 28.3 26.7 29.1 29.7 19.9 27.2 0.91 123 1.66 0.84 1.99 0.35
91 Hemkanta                760020f 64 M 1.6 69 27 Gr3 Y Y 1 N Y Y N N N N 88 160 80 14 0.98 168 92 44 110 122 124 6 18.9 160 33.7 34.8 30.4 25.7 23.3 19.8 28.3 1.24 156 5.68 1.28 2.09 0.3
92 Naba kumar Ghosh        762088f 43 M 1.6 68 27 Gr3 Y Y 1 N Y Y N N N N 84 146 100 13 1 109 161 31 59 110 91 6 8.02 65 22.3 22.4 22.2 19.3 20.1 20.4 21.3 1.13 128 2.18 0.9 2.04 0.34
93 Ramlakhan               379828f 61 M 1.6 70 27 Gr3 Y Y 1 N Y Y N N N N 88 150 90 11 1.1 189 191 27 142 91 118 5 7.43 58 31.6 29.2 30.8 23 21.3 20.4 27.8 1.39 156 1.67 0.87 1.96 0.35
94 Rajkumar Bhagat         762123f 59 M 1.6 72 28 Gr3 Y Y 1 N Y Y N N N N 80 148 90 13 1 127 78 40 69 104 130 6 7.78 56 27.7 24.7 25.6 28.5 29.1 19.9 26.4 0.89 119 2 0.89 2.02 0.34
95 Amarsh Bhal             762074f 73 M 1.6 71 27 Gr3 Y Y 1 N Y Y N N N N 88 160 98 10 0.98 120 75 52 60 94 84 6 7 52 27.2 26.2 20.2 27.1 26.8 19.7 23.2 0.75 76 1.62 0.85 1.97 0.35
96 Kailash Mahato          324736f 54 M 1.6 68 28 Gr3 Y Y 1 N Y Y N N N N 70 150 106 15 0.91 176 77 40 122 102 153 6 17 76 33 29.3 34.8 33.7 33.5 20.8 33.3 1.04 277 4.28 1.23 2.01 0.31
97 Robert                  761510f 48 M 1.7 68 23 Gr2 Y Y 2 N Y Y N N N N 68 148 100 14 1.2 176 430 42 65 88 82 5 5.7 39 22.5 22.7 20.5 23.4 21 20 21.3 0.92 66 1.24 0.76 1.94 0.37
98 Baju                    713960f 52 M 1.7 78 28 Gr3 Y Y 1 N Y Y N N N N 88 168 90 14 1.3 144 281 31 79 88 113 6 14.4 82 26.7 25.8 26.4 21.8 20.9 19.3 24.2 1.24 96 3.13 1.16 1.94 0.32
99 Surimal Sen             372818f 61 M 1.6 74 30 Gr3 Y Y 1 N Y Y N N N N 80 148 90 15 1 204 226 35 130 100 118 6 7.65 60 27.1 27.3 33.8 30.8 28.2 24.2 30.9 1.15 168 1.89 0.88 2 0.35
100 Banun Tora              762881f 43 M 1.6 68 27 Gr3 Y Y 1 N Y Y N N N N 110 160 100 20 1 153 188 32 99 92 111 5 7.02 70 15.9 16.8 17.8 13.8 14.4 19.9 16.6 1.27 105 1.59 0.85 1.96 0.36
101 Bipandaram Mondal       765984F 40 M 1.6 75 29 Gr3 Y Y 1 N Y Y N N N N 100 150 90 13 1.2 116 100 33 67 86 89 5 15.6 104 16.7 17.5 16.7 15.9 17.4 19.5 17 1 82 3.32 1.19 1.93 0.32
102 Bijay Tapno             766103f 41 M 1.8 79 26 Gr3 Y Y 1 N Y Y N N N N 106 160 98 13 1 159 109 35 102 84 86 5 17.5 118 22.5 20.5 21.6 17.8 18 20.3 20.2 1.21 98 3.63 1.24 1.92 0.32
103 Jada Debnath            969656a 57 M 1.5 70 33 Gr4 Y Y 1 N Y Y N N N N 88 168 90 13 0.82 169 187 47 102 103 138 6 17.3 99 24.1 22.7 29.8 26 24.8 24.1 27.2 1.17 90 4.4 1.24 2.01 0.31
104 Sharman Agrawal         762797f 58 M 1.7 74 26 Gr3 Y Y 1 N Y Y N N N N 80 106 70 14 1.1 212 146 38 143 105 152 5 10.8 88 23 21.8 29 27 25 23 28 1.2 98 2.8 1.03 2.02 0.33
105 Ashish kumar Basu       749542f 52 M 1.7 68 25 Gr2 Y Y 2 N Y Y N N N N 68 150 90 14 1.1 149 92 37 96 98 88 6 12.7 108 22.6 21.8 26.8 23.2 23 22.4 24.8 1.16 107 3.07 1.1 1.99 0.32
106 Milan kanti biswas      747078f 46 M 1.7 80 29 Gr3 Y Y 1 N Y Y N N N N 78 160 88 15 0.88 240 412 35 137 118 120 5 17.1 84 23.2 25.2 31.9 24.8 25.8 20.4 28.3 1.26 188 4.98 1.23 2.07 0.3
